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 ABSTRACT  
 
The cramping, and often debilitating, pain which women of child-bearing age experience in 
the lower abdomen just before, or during, menstruation, in the absence of any pelvic 
pathology, is called primary dysmenorrhoea. The aetiology of dysmenorrhoea is not fully 
understood and the condition is often poorly treated. The aim of my thesis is to contribute 
knowledge to the assessment and treatment of dysmenorrhoea, as well as objective 
measurement of the impact of dysmenorrhoea on physical activity and functional performance. 
I completed three separate studies, on three different groups of healthy young women with a 
history of moderate-to-severe primary dysmenorrhoea. I used the McGill Pain Questionnaire 
(MPQ) and the visual analogue scale (VAS), as indices of pain intensity, to assess the efficacy 
of three cycloxygenase (COX) inhibitors, covering a spectrum of COX-2 selectivity, in the 
treatment of dysmenorrhoea. The pain response index (PRI) and present pain index (PPI), 
calculated from the MPQ, and the VAS, were highly correlated as measures of intensity of 
dysmenorrhoeic pain. The COX-2 specific inhibitor rofecoxib, and the non-selective COX 
inhibitor diclofenac potassium, significantly decreased the duration of dysmenorrhoeic pain, 
compared to placebo and compared to meloxicam, a COX-2 selective inhibitor, and were 
equally effective in relieving menstrual pain. 
 
Women with dysmenorrhoea subjectively report decreased physical activity, but no studies 
have attempted to quantify the decrease in exercise performance, or functional ability resulting 
from dysmenorrhoea, in a standardized laboratory protocol when women perform structured 
physical activity. Furthermore, no method or tool has been described which measures the 
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effect of dysmenorrhoea on the activity of daily life. I assessed whether an activity data logger 
(actigraphy), worn on the hip, was able to detect, and quantify, pain-reduced physical activity 
levels in women with dysmenorrhoea going about their daily lives. In the laboratory protocol I 
showed that moderate-to-severe dysmenorrhoea, but not the act of menstruation without pain, 
decreased the women’s ability to bend over and stretch upwards, and to perform exercise that 
required the use of their lower limb muscles. Administration of diclofenac potassium 
attenuated dysmenorrhoea and restored exercise performance and functional ability to levels 
attained when the women were in a pain-free phase of the menstrual cycle.  I showed that 
activity data loggers, worn on the hip of each woman, were able to detect and quantify pain-
reduced activity of daily life. Moderate-to-severe menstrual pain, but not menstruation itself, 
decreased the women’s physical activity, as measured by the data loggers, to about two-thirds 
of the activity measured when they were in a pain-free phase of the menstrual cycle.  
 
In conclusion, I have added further knowledge to the assessment and treatment of 
dysmenorrhoea. The VAS and the MPQ, incorporating the PRI and PPI, are interchangeable 
indices of intensity of dysmenorrhoea and, depending on the educational status of the cohort, 
any one of the indices is suitable for assessment of intensity of pain. Rofecoxib and diclofenac 
potassium, two cycloxygenase inhibitors with differing COX-2 specificity, are excellent 
pharmacological therapies for the treatment of dysmenorrhoea. Objective assessment of 
physical activity, via activity data loggers, is a potentially useful tool to investigate the effects 
of dysmenorrhoea on structured physical activity and the activity of daily life, and for 
measuring pain-related debilitation and its management.  
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1. Introduction 
 
The cramping pain which women of child-bearing age experience in the lower abdomen just 
before menstruation or during menstruation, in the absence of any pelvic pathology, is called 
primary dysmenorrhoea (Dawood, 1985; Dawood, 1990; Coco, 1999; French, 2005; Dawood, 
2006). In comparison, secondary dysmenorrhoea is characterized by lower abdominal pain that 
occurs not only before or during menstruation, but at other times of the menstrual cycle, and is 
related to pelvic abnormalities such as endometriosis and uterine malformations (Dawood, 1982; 
Coco, 1999; Harel, 2002; Dawood, 2006; Harel 2006).  
 
Primary dysmenorrhoea can be diagnosed by the history and symptoms experienced by a woman. 
Typically, the cramp-like lower abdominal pain begins within two years after menarche, a time 
when normal ovulatory cycles have been established (Dawood, 1985; Harel, 2002; Dawood, 
2006). The pain, which usually begins just before or during menstruation and lasts for two to 
three days, can range from mild to severe, and often is associated with other complaints such as 
fatigue, headache, diarrhoea, nausea, vomiting and backache (El-Gilaney et al., 2005). Menstrual 
pain that begins more than four years after menarche usually is indicative of secondary 
dysmenorrhoea, and a pelvic examination or laparoscopy often is required to confirm the 
diagnosis (Dawood, 1985).   
 
Reported prevalence rates for primary dysmenorrhoea are as high as 50 to 90 percent (Zondervan 
and Yudkin, 1988; Sundell et al., 1990; Ng et al., 1992; Davis and Westhoff, 2001; Banikarim et 
al., 2000; Tonini, 2002; Sharma and Gupta, 2003; Strinic et al., 2003; Houston et al., 2006; Lee et 
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al., 2006), with about 15 to 33 percent of women with dysmenorrhoea reporting moderate-to-
severe menstrual pain (Andersch and Milsom, 1982; Davis and Westhoff, 2001; El-Gilany et al., 
2005; Patel et al., 2006). 
 
The detrimental impact of dysmenorrhoea on the lives of women is under-appreciated. In many 
countries, dysmenorrhoea is the leading cause of recurrent short-term school and work 
absenteeism in adolescent girls and women (Klein and Litt, 1981; Banikarim et al., 2000), and it 
has a negative impact on social, academic and sports activities in female adolescents (Banikarim 
et al., 2000).  In several longitudinal studies of young woman, rates of absenteeism ranged from 
34 to 50 percent (Andersch and Milsom, 1982; Johnston, 1988; Sundell et al., 1990). In a study of 
Canadian women, 50 percent of the women with dysmenorrhoea reported that their activities had 
been limited, and 17 percent reported missing school or work because of menstrual pain (Burnett 
et al., 2005). Hispanic female adolescents have reported that activities affected by dysmenorrhoea 
include concentration in class, class participation, socialisation, homework, test-taking skills, 
grades and sports participation (Banikarim et al., 2000). Indeed, as reported by many studies, 
there is considerable cost to both the individual and to society as a result of dysmenorrhoea. In 
the mid 1980’s, absenteeism among women suffering severe symptoms in the United States has 
been estimated to cause 600 million lost working hours or two billion dollars annually (Dawood, 
1982).   
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2. Aetiology of primary dysmenorrhoea 
 
Dysmenorrhoea is thought to result from excessive muscular contraction of an ischaemic uterus 
(Harel, 2002; Dawood, 2006). The measurement of intra-uterine pressure, an indication of uterine 
contractility, in women with dysmenorrhoea and in women without dysmenorrhoea, has been 
crucial in understanding the aetiology of primary dysmenorrhoea. Women experiencing 
dysmenorrhoea, when compared to women without dysmenorrhoea in the menstrual phase of the 
cycle, have an increase in resting uterine tone, active intra-uterine pressure and number of 
contractions, which decrease myometrial blood flow and cause uterine ischaemia (Ylikorkala and 
Dawood, 1978; Dawood, 1985; Dawood, 2006). Doppler flow studies have confirmed that the 
blood flow within the uterine arteries of women with dysmenorrhoea on their first day of 
menstruation, compared to that of women without dysmenorrhoea, was significantly decreased as 
a result of increased myometrial activity (Altunyurt et al., 2005).  The increased production and 
release of biologically active compounds that increase myometrial activity and decrease uterine 
blood flow, such as prostaglandins, leukotrienes and vasopressin, have been implicated in the 
pathogenesis of primary dysmenorrhoea.  
 
2.1. Vasopressin  
 
Although there is substantial evidence supporting the involvement of prostaglandins (see 2.2.2), 
and to a lesser extent leukotrienes (see 2.2.1), in the pathogenesis of primary dysmenorrhoea, 
there also is evidence for an involvement of vasopressin in the mechanism of primary 
dysmenorrhoea (Akerlund, 2004). The ability of vasopressin, via V1a receptors, to stimulate the 
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smooth muscle of the myometrium and uterine arteries in non-pregnant women, raises the 
possibility that vasopressin may be a pathophysiological factor in the increased myometrial 
activity and reduced uterine blood flow associated with primary dysmenorrhoea (Akerlund et al., 
1976; Bossmar et al., 1995).  Indeed, women with primary dysmenorrhoea have an increased 
plasma concentration of vasopressin (Akerlund et al., 1979; Stromberg et al., 1984; Ekstrom et 
al., 1992). Hauksson et al. (1988) showed that in women without dysmenorrhoea, an infusion of 
vasopressin, on the first or second day of menstruation, decreased local endometrial blood flow, 
stimulated uterine activity and caused slight to moderate dysmenorrhoeic-like pains.  The 
aetiological role of vasopressin in primary dysmenorrhoea is supported by the pain relief that 
women with dysmenorrhoea obtained when given a vasopressin V1a receptor antagonist (Brouard 
et al., 2000). However, some investigators have not been able to confirm elevated plasma 
vasopressin in women with primary dysmenorrhoea and found that a vasopressin antagonist had 
no effect on intrauterine pressure, blood flow or pain in women with dysmenorrhoea (Valentin et 
al., 2000). Therefore, despite the ability of vasopressin to cause uterine contractility, and possibly 
ischaemic pain, the involvement of vasopressin in the pathogenesis of dysmenorrhoea is 
controversial (Valentin et al., 2000). Of more importance in the pathogenesis of dysmenorrhoea 
is the role of two of the eicosanoids, namely leukotrienes and prostaglandins, which are able to 
induce abnormal uterine contractions (Dawood, 2006).   
 
2.2. Eicosanoids  
 
The pathophysiology of primary dysmenorrhoea is thought to result mainly from an excessive 
production and release of two classes of the eicosanoids, namely prostaglandins and leukotrienes 
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(Ylikorkala and Dawood, 1978; Bygdeman et al., 1979; Dawood, 1981; Dawood, 1982; Nigam et 
al., 1991; Coco, 1999; Deligeoroglou, 2000; Tonini, 2002; French, 2005; Dawood, 2006; Harel, 
2006). Prostaglandins, together with leukotrienes, prostacyclins and thromboxanes are the major 
constituents of a group of biologically active oxygenated fatty acids, the eicosanoids (Henderson, 
1991). Eicosanoids are formed by most cells of the body and act as autocrine and paracrine lipid 
mediators (Funk, 2001). Eicosanoids are not stored but are synthesized de novo from 20-carbon 
essential fatty acids, a common component of cell membrane phospholipids, through a cascade of 
enzymes, when cells are activated by mechanical trauma or by specific cytokines, hormones or 
growth factors (Henderson, 1994; Funk, 2001). For the purposes of this chapter, I will only focus 
on the eicosanoids that are synthesized from arachidonic acid, an abundant essential omega-6 
fatty acid that is selectively cleaved from the cell membrane by the enzyme cytosolic 
Phospholipase A2 (cPLA2) (Figure 1) (Glaser et al., 1993; Evans et al., 2001).  
    
There are three major pathways for metabolism from arachidonic acid as the substrate; the 
cycloxygenase, lipoxygenase and epoxygenase pathways (Abu and Konje, 2000). The 
cycloxygenase pathway leads to the formation of the prostanoids (prostaglandins, prostacyclins 
and thromboxanes), while the lipoxygenase pathway is responsible for initiating the synthesis of 
leukotrienes (Demers et al., 1985). The epoxygenase pathway leads to the formation of 
prostaglandin epoxides which play a role in regulating cellular proliferation, inflammation, fever 
and haemostasis (Zeldin, 2001). Because prostaglandins and leukotrienes are implicated in the 
pathogenesis of dysmenorrhoea, only the cycloxygenase and lipoxygenase pathways will be 
discussed in detail here. 
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Figure 1. Schematic representation of the synthesis of eicosanoids from arachidonic acid 
(adapted from Funk, 2001). 
cPLA2 : cytosolic Phospholipase A2; PGE2 : Prostaglandin E2; PGF2 alpha : Prostaglandin F2 
alpha; PGD2 : Prostaglandin D2  
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2.2.1. Leukotrienes  
 
Figure 2 depicts schematically the synthesis of leukotrienes, from arachidonic acid, via the 
lipoxygenase pathway, which is active in leukocytes, including mast cells, eosinophils, 
neutrophils, monocytes and basophils (Funk, 2001). When these cells are activated, arachidonic 
acid is liberated from cell membrane phospholipids by cPLA2. Arachidonic acid is then donated 
by the 5-lipoxygenase activating protein (FLAP) to the enzyme 5-lipoxygenase, which converts it 
into 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and then into leukotriene A4 (LTA4). In cells 
with the enzyme LTA4 hydrolase, such as neutrophils and monocytes, LTA4 is converted to 
leukotriene B4 (LTB4), which is a powerful chemo-attractant for neutrophils (Abu and Konje, 
2000). In cells that express the enzyme LTC4 synthase, such as mast cells and eosinophils, LTA4 
is conjugated with glutathione to form leukotriene C4 (LTC4) (Abu and Konje, 2000). In many 
biological systems LTC4 is then rapidly converted to leukotriene D4 (LTD4) via the enzyme 
transpeptidase. LTD4 may then be converted to leukotriene E4 (LTE4) by the action of the enzyme 
dipeptidase (Abu and Konje, 2000). 
 
The main sites of leukotriene production in the body are the lungs and the uterus (Nigam et al., 
1991; Biegelmayer et al., 1995), but leukotrienes also can be produced in the kidneys, skin, 
coronary circulation and bile ducts (Abu and Konje, 2000). The leukotriene receptors are located 
in the plasma membranes of smooth muscle cells, and binding of the leukotriene to the receptor 
causes the contraction of smooth muscle, chemotaxis, and increased vascular permeability (Abu 
and Konje, 2000). Leukotrienes are potent vasoconstrictors and stimulate uterine muscle 
contractions (Carraher et al., 1983), which cause ischaemically-induced uterine pain  
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Figure 2. Schematic representation of the synthesis of leukotrienes from arachidonic acid 
(adapted from Abu and Konje, 2000). 
cPLA2 :  cytosolic Phospholipase A2 ; 5-HPETE : 5-hydroperoxyeicosatetraenoic acid 
LTB4 : Leukotriene B4 ; LTC4 : Leukotriene C4 
LTD4 : Leukotriene D4 ; LTE4 : Leukotriene E4  
 
 10 
(Dawood, 2006). Experimental studies (Demers et al., 1994) using human endometrium and 
myometrium show the capacity of these tissues to synthesize leukotrienes. Furthermore, evidence 
from in-vitro studies has shown that the production of leukotrienes by the endometrium from 
women with dysmenorrhoea is significantly higher than that from women without 
dysmenorrhoea (Rees et al., 1987; Nigam et al., 1991; Biegelmayer et al., 1995; Harel et al., 
2004). Nigam et al. (1991) also found a correlation between the severity of dysmenorrhoea in 
women with primary dysmenorrhoea and the concentration of LT-C4/D4 in their menstrual fluid, 
and an increase in urinary LTE4 has been found in adolescent girls with dysmenorrhoea (Harel et 
al., 2004).  
 
However, the ability of a leukotriene receptor antagonist to attenuate primary dysmenorrhoea, in 
well-controlled studies, has yet to be shown. Two adolescent girls with chronic pelvic pain 
showed a decrease of more than 50% in pain intensity after two to three months of treatment with 
montelukast, a leukotriene receptor antagonist (Dietrich et al., 2003). However, sample size was 
small and there was no control group. In a more recent randomised, double-blind, crossover 
study, 25 adolescent girls with dysmenorrhoea received either a daily tablet of montelukast, or 
one daily tablet of placebo, for the luteal and menstrual phase of three consecutive menstrual 
cycles (Harel et al, 2004). The results do not support the use of montelukast, in the given dose, 
for treatment of primary dysmenorrhoea. The investigators suggest that a higher dose, or 
prolonged daily use of the drug, may alleviate the symptoms of dysmenorrhoea in the adolescent 
girls. However, until more evidence exists for the successful treatment of primary dysmenorrhoea 
with leukotriene receptor antagonists, the clinical importance of leukotrienes in the aetiology of 
primary dysmenorrhoea remains unresolved.  
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2.2.2. Prostaglandins    
 
Advances in the last three decades implicate prostaglandins as the primary agents in the 
pathogenesis of dysmenorrhoea (Dawood, 2006). Excessive production and release of 
endometrial prostaglandins (PG), especially PGF2 alpha, at menstruation causes increased uterine 
contraction, reduced blood flow and uterine ischaemia. Contraction of an ischaemic myometrium 
and hyper-sensitisation of pain fibres by PGE2 causes pain (Chan and Hill, 1978; Ulmsten, 1985; 
Altunyurt et al., 2005).  
      
Figure 3 schematically depicts the synthesis of the prostanoids (prostaglandins, prostacyclins and 
thromboxanes), from arachidonic acid, via the cycloxygenase (COX) pathway. At the 
endoplasmic reticulum and nuclear membrane, the arachidonic acid that has been released by 
cytosolic Phospholipase A2 (cPLA2), is metabolised into the unstable endoperoxides PGG2 and 
PGH2 by cycloxygenase (COX). The cyclic endoperoxide (PGH2) is metabolised by cellular-
specific enzymes (synthases) into the prostaglandins of PGD2, PGE2 and PGF2 alpha as well as 
thromboxane (TXA2) and prostacyclin (PGI2) (Funk, 2001).  
 
Until 1990, it was thought that COX existed as a single enzyme, and this enzyme was responsible 
for the formation of the common prostaglandin precursor, PGH2, which, in a cell-specific 
fashion, was exposed to different cellular-specific enzymes that resulted in the formation of the 
prostanoids (McMurray and Hardy, 2002). Around 1990, Simmons and colleagues discovered 
two closely related forms of the COX enzyme, cycloxygenase-1 (COX-1) and cycloxygenase-2  
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Figure 3. The arachidonic acid cascade showing the cycloxygenase (COX) pathway, the biosynthesis of the cyclic 
endoperoxide, PGH2, and the final prostanoids: PGE2, PGF2 alpha, PGD2, PGI2 and TXA2. The cell-specific enzymes 
(synthases) which result in the formation of the prostanoids in their specific cells are shown in italics. Diagram 
adapted from Funk (2001). 
cPLA2 : cytosolic Phospholipase A2; COX : cycloxygenase; COX-1 : cycloxygenase-1; COX-2 : cycloxygenase-2; 
PGH2 : Prostaglandin H2; PGI : Prostacyclin; PGF : Prostaglandin F; PGD : Prostaglandin D; PGE2 : Prostaglandin 
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(COX-2) (Botting, 2006). Both of these isoenzymes synthesise arachidonic acid into the common 
prostanoid precursor (PGH2) and subsequent modification through the cell- and stimulus-specific 
synthases leads to local prostanoid release, with variable functional consequences (McMurray 
and Hardy, 2002). 
 
Initial investigations suggested that COX-1 was synthesised at a constant rate regardless of 
physiological demand and was responsible for the production of prostanoids with a number of 
regulatory and homeostatic, or “housekeeping,” functions in the upper gastrointestinal tract, 
kidney and platelets (Smith et al., 2000; McMurray and Hardy, 2002). For example, COX-1 
results in the production of prostacyclin (PGI2), which, when released from the endothelium is 
anti-thrombotic, and when released by the gastric mucosa is cyto-protective (Vane et al., 1998). It 
is also COX-1 in platelets that causes thromboxane (TXA2) production, causing aggregation of 
the platelets to prevent inappropriate bleeding (Vane et al., 1998). In the kidney, PGE2 and PGI2 
influence total renal blood flow, distribution of renal blood flow, sodium and water re-absorption 
and renin release (Frolich, 1997). These functions, with the exception of renin secretion, are 
COX-1 dependent (Frolich, 1997). However, the constitutively expressed isoform, COX-1, has 
also been suggested to play a role in the inflammatory process (Smith et al., 1998); recent data 
suggests that COX-1 may play an important role in pain processing and sensitization in the rat 
spinal cord after surgery (Zhu et al., 2003).  
 
The COX-2 enzyme was thought to be induced in response to inflammatory stimuli such as 
cytokines and bacterial lipopolysaccharides, rather than expressed under normal cellular function 
(Hinz and Brune, 2002). However, there is increasing evidence that in some tissues such as the 
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brain, reproductive organs (ovaries, uterus), kidney, and placenta (during late gestation), COX-2 
also is synthesised at a constant rate, and is responsible for the synthesis of prostanoids 
responsible for regulatory and homeostatic functions in these tissues (Hinz and Brune, 2002; 
Mitchell and Warner, 2006). For example, laminar shear stress in blood vessels up-regulates the 
COX-2 formation of the anti-thrombotic prostanoid, prostacyclins (Topper et al., 1996; Inoue et 
al., 2002). In the female reproductive tract, COX-2 and the resultant prostaglandins play an 
important role in ovulation, implantation and labour (Mitchell et al., 1995; Richards et al., 1995; 
Akil et al., 1996; Sirois et al., 2004). There also is evidence that constitutively expressed COX-2 
may play a role in physiological renal functions. COX-2 derived prostaglandins released from 
epithelial cells in the macula densa of the kidney are involved in the control of renin secretion 
(Traynor et al., 1999). Another important finding is that COX-2 may be involved in the 
angiogenesis associated with ulcer healing (Mizuno et al., 1997). However, COX-2 usually is 
absent from most tissues but is expressed rapidly in response to a local stimuli such as pro-
inflammatory cytokines. The resultant formation of prostaglandins are involved in 
pathophysiological conditions such as acute and chronic inflammation, hyperalgesia, osteo-
arthtitis, glomerulo-nephritis, rheumatoid arthritis, dysmenorrhoea, carcinogenesis and 
Alzheimer’s disease (Hinz and Brune, 2002; McMurray and Hardy, 2002).  
 
2.2.2.1. Role of prostaglandins in menstruation  
 
Prostaglandins are recognized as key molecules in human reproduction (Sales and Jabbour, 
2003). In the female reproductive tract, COX-2 expression increases substantially at mid-cycle, 
and the resultant prostaglandins play an important role in rupture of the follicle (Richards et al., 
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1995; Akil et al., 1996; Sirois et al., 2004). With fertilization, COX-2 expression increases in the 
endometrium surrounding the implantation site (Chakraborty et al., 1996), and the resultant 
prostaglandins are crucial for successful implantation and angiogenesis. Transgenic mice that 
lack the COX-2 enzyme are infertile, while those missing only the COX-1 enzyme have normal 
reproduction (Lim et al., 1997). There is a rapid increase in COX-2 expression in the placenta and 
amnion immediately before and during labour (Mitchell et al., 1995). Furthermore, 
prostaglandins play a role in myometrial contraction and inhibition of COX-2 delays labour 
(Mitchell et al., 1995).  
 
The process of menstruation, which involves the shedding of the endometrial lining in the 
absence of fertilization, also is dependent on prostaglandins (Smith et al., 1981; Poyser, 1995; 
Baird et al., 1996). Peri-vascular cells which surround the spiral arteries of the endometrium, via 
progesterone receptors, are responsive to changes in progesterone concentration (Perrot-Applanat 
et al., 1994). During the luteal phase of the menstrual cycle, a time when progesterone 
concentration is high, progesterone binds to the peri-vascular cell membrane receptors which 
inactivates the intra-cellular protein-complex, nuclear factor-kappa B (NF-Kappa B), and 
decreases the formation of pro-inflammatory cytokines (Allport et al., 2001). In the absence of 
progesterone, as would occur in the late-luteal phase of the menstrual cycle, NF-Kappa B is 
activated, and the peri-vascular cells express chemokines and pro-inflammatory cytokines (Kelly 
et al., 2002). The pro-inflammatory cytokines (tumour- necrosis-factor alpha (TNF alpha) and 
interleukin-8 (IL-8)) bind to their respective peri-vascular receptors and cause the formation of 
PGE2 and PGF2 alpha (Funk, 2001; Hinz and Brune, 2002). PGE2, and the pro-inflammatory 
cytokine IL-8, are responsible for the influx of neutrophils into the endometrial tissue that are a 
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potent source of collagenase and elastase enzymes (Kelly et al., 2002). Collagenase will disrupt 
inter-cellular anchoring and facilitate the process of tissue shedding (Kelly et al., 2002). PGF2 
alpha, a potent endometrial blood vessel vasoconstrictor, and myometrial smooth muscle 
contractor (Downie et al., 1974; Martin and Bygdeman, 1975; Bygdeman et al., 1979; Jensen et 
al., 1987; Mitchell et al., 1995), causes ischaemia and therefore necrosis of the endometrial cells, 
and the myometrial contraction results in shedding of the endometrial tissue (Kelly, 2002).   
 
The role of PGF2 alpha as a precursor to menstruation is supported by findings of the high 
concentrations of this prostaglandin in the endometrium and menstrual fluids of women during 
the menstrual phase, compared to the follicular and early-luteal phase of the menstrual cycle 
(Downie et al., 1974; Singh et al., 1975; Matsukawa and Ninagawa, 1980; Vijayakumar and 
Walters, 1981; Jensen et al., 1987). It is likely that the formation of PGF2 alpha is COX-2 
dependent, since in vitro studies have shown that inhibitors of the COX-2 isoenzyme have 
significant relaxant effects on myometrial contractility (Slattery et al., 2001; Dore et al., 2002). In 
addition, the COX-2 isoform has been localized in the peri-vascular cells and the glandular 
epithelium of the human endometrium throughout the menstrual cycle with a significant increase 
in COX-2 immuno-staining intensity observed premenstrually (Jones et al., 1997; Slater et al., 
1999).  
 
2.2.2.2. Prostaglandins and dysmenorrhoea  
 
There is substantial evidence for the involvement of prostaglandins, especially PGF2 alpha, in the 
pathogenesis of primary dysmenorrhoea. First, studies, both recent and old, have documented 
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dysmenorrhoea in women who have significantly higher than normal concentrations of 
prostaglandins in their endometria (Pickles, 1967), endometrial jet washings (Halbert et al., 1975) 
and endometrial fluids (Lumsden et al., 1983; Rees et al., 1984; Zahradnik and Breckwoldt, 
1984). Chan and Dawood (1980) confirmed that women with dysmenorrhoea, compared to 
eumenorrhoeic women, have twice the amount of PGF2 alpha in their menstrual fluid. Secondly, 
pharmacological agents such as COX inhibitors, which are able to decrease the production of 
prostaglandins, have been shown to be effective in the treatment of primary dysmenorrhoea 
(Marjoribanks et al., 2003; Dawood et al., 2006). Thirdly, the systemic administration of 
exogenous PGF2 alpha to women without dysmenorrhoea, in the menstrual phase, causes 
contraction of the non-pregnant uterus (Martin and Bygdeman, 1975), and subsequent lower-
abdominal pain that is similar in nature and quality to the pain experienced by women with 
dysmenorrhoea (Dawood, 1981; Paz et al., 2002). Metabolites such as bradykinin, oxygen-
derived free radicals and lactic acid, which are produced during uterine ischaemia, stimulate the 
ischaemically-sensitive visceral nociceptors, and pain is felt (Stahl and Longhurst, 1992). 
Furthermore, PGE2 sensitises peripheral uterine nociceptor terminals and produces localised pain 
hypersensitivity (Hinz and Brune, 2002). 
 
In dysmenorrhoea, and other painful conditions, an understanding of the aetiology of the pain is 
essential in proposing pharmacological treatments for the alleviation of the pain. In order to 
effectively treat pain, it is essential to measure the intensity and quality of pain so that the 
antinociceptive efficacy of medications can be proven (Melzack and Katz, 2006).  
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3. Measurement of pain 
 
“Just as ‘my pain’ belongs in a unique way only to me, so I am utterly alone with it. I cannot 
share it. I have no doubt about the reality of the pain experience, but I cannot tell anybody what I 
experience. I surmise that others have ‘their pain’, even though I cannot perceive what they mean 
when they tell me about them. I am certain about the existence of their pain only in the sense that 
I am certain of my compassion for them. And yet, the deeper my compassion, the deeper is my 
certitude about the other person’s utter loneliness in relation to his experience.”  (Illich, 1976; 
Quote taken from Turk and Melzack, 2001, pg 147-148). 
 
According to Melzack and Katz (2006), “pain is a personal, subjective experience that comprises 
sensory-discriminative, motivational-affective and cognitive-evaluative dimensions” (Melzack 
and Katz, 2006; pg. 291). Because pain is subjective, the patients’ self-reports provide the most 
valid measure of the experience. 
 
3.1. Assessment of intensity of pain 
 
In clinical and research settings, the most common methods used to measure pain intensity are 
verbal rating scales, numerical rating scales and visual analogue scales (Melzack and Katz, 
2006). Verbal rating scales consist of a series of verbal pain descriptors listed from least to most 
intense (e.g., no pain, mild, moderate and severe), whereas numerical scales require the patient to 
choose a numerical value which corresponds to their intensity of pain (e.g., 0=no pain, 1=mild 
pain, 2=moderate pain and 3 =severe pain). The visual analogue scale (VAS) consists of a 
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100mm horizontal or vertical line with the two end points anchored at ‘no pain’ and ‘worst pain 
ever’ (Melzack and Katz, 2006). Patients are required to make a mark on the line which best 
represents their pain intensity and the distance in millimetres is used as a numerical index of the 
intensity of pain.  
 
Although research has shown that the three types of scale correlate highly with each other (Bijur 
et al., 2003; Ekblom and Hansson, 1988), the VAS has emerged as a superior scale to measure 
intensity of pain because of its ratio scale properties (Price et al., 1983; Price and Harken, 1987). 
Therefore, VAS measurements obtained at multiple points in time, or from different patients, can 
be used to calculate percentage differences in pain intensity (Bijur et al., 2001). Furthermore, the 
VAS has proven to be a valid and reliable measure of acute and chronic pain intensity (Kelly, 
1988; Libman et al., 2000). More recently, the numerical Box-21 scale, a combination of the 
numerical rating scale and the VAS, has emerged as an accurate and reliable measure of pain 
intensity in heterogeneous patient groups (Peters et al., 2007).  
 
In studies investigating the antinociceptive efficacy of drugs in alleviating dysmenorrhoea, the 
scales used most commonly to measure intensity of pain are the verbal rating scale, numerical 
rating scale and VAS. The primary reason for their popularity is that they are quick and easy to 
administer, and can be used with minimal supervision in studies with large cohorts of women. As 
yet, the numerical Box-21 scale has not been used by researchers to assess the intensity of 
dysmenorrhoea.   
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3.2. Assessment of the multidimensional nature of pain 
 
Although useful in measuring intensity of pain, the VAS, numerical rating scales and verbal 
rating scales assume that pain is a one-dimensional experience that can be measured with a 
single-item scale (Melzack, 1975). The word “pain” refers to an endless variety of qualities, with 
each type of pain having different sensory qualities, affective or emotional qualities and 
autonomic responses (Melzack and Katz, 2006). Therefore, the McGill Pain Questionnaire 
(MPQ) was developed by Melzack and Torgerson in 1975 as a tool to measure, subjectively and 
quantitatively, a patient’s unique experience of pain (Wilkie et al., 1980). The two main measures 
of the MPQ are the pain rating index (PRI) and the present pain intensity (PPI). The PPI is 
recorded as a number from 0 to 5, in which each number is associated with the following words: 
0, no pain; 1, mild; 2, discomforting; 3, distressing; 4, horrible and 5, excruciating. Whereas the 
PPI is a measure of the intensity of pain, the PRI reflects the patient’s perception of the sensory, 
affective, evaluative and mode of pain and is recorded as a numerical value. The PRI consists of 
20 subclasses of words divided into four major classes proposed in Melzack’s theory of pain: 
words concerned with the sensory qualities of pain, words describing the affective qualities of 
pain, evaluative words that describe the subjective overall intensity of the total pain experience 
and words that describe the mode of pain (Melzack, 1975). The patient is asked to select the one 
word from each subclass that most accurately describes their pain at that time. If none of the 
words apply, none are chosen. Each word descriptor chosen by the patient is assigned a pre-
determined numerical value which when added together calculate a PRI score for sensory pain, 
affective pain, evaluative pain and mode of pain (Melzack, 1975). The MPQ has become a 
reliable and valid tool to measure a patient’s unique experience of the intensity and quality of 
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pain (Wilkie et al., 1980; Chen et al., 1989), and has therefore been used widely in the study of 
acute, chronic and laboratory-produced pains (Melzack and Katz, 2006). Furthermore, the MPQ 
is sensitive to intervention-based studies designed to reduce pain (Dwork et al., 2003; Lynch et 
al., 2003), and is able to distinguish between various pain syndromes (Wilkie et al., 2001; 
Mongini et al., 2003). However, successfully administration of the MPQ does require the patient 
to be fluent in the language of the MPQ.  
 
In keeping with multiple dimensions of pain, the Descriptor Differential Scale (DDS) was 
developed by Gracely et al. in 1978 (Gracely and Kwilosz, 1988). The scale is a list of 12 
adjectives of pain intensity, and the patient is required to rate pain intensity in each of the 12 
categories according to a 21-point scale (Gracely and Kwilosz, 1988). Although time-consuming 
and often difficult to administer, the DDS has been shown to be a reliable and valid instrument 
with ratio scale properties (Doctor et al, 1995). 
 
In studies investigating the antinociceptive efficacy of drugs in alleviating dysmenorrhoea, the 
DDS has not been used as a tool to assess the quality of pain. In comparison, the MPQ has been 
used to assess the quality of menstrual pain in some studies (Reading, 1979; Brodie and Niven, 
2000, Grace and MacBride-Stewart, 2007). One of the studies aimed to compare the women’s 
descriptions of dysmenorrhoea, when talking about their pain in narrative mode, with the 
descriptors used in the MPQ (Grace and MacBride-Stewart, 2007). A predominance of an 
affective dimension of pain was evident in the women’s narratives, although few of these words 
appear in the MPQ (Grace and MacBride-Stewart, 2007). However, the women’s narratives 
contained many of the sensory words listed in the MPQ (Grace and MacBride-Stewart, 2007). In 
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conclusion, the MPQ was found to be a consistent and accurate representation of dysmenorrhoeic 
pain. In this study by Grace and MacBride-Stewart (2007), the words most frequently chosen to 
describe dysmenorrhoea, by more than one third of the women, were “cramping”, “tiring” and 
“aching. Similarly, more than one third of the women in another study by Brodie and Niven 
(2000), listed “cramping”, “tiring”, “aching”, “tender”, ‘miserable” and “nagging” as words to 
describe their dysmenorrhoea. Although the MPQ has been used to assess the quality of 
menstrual pain in some studies (Reading, 1979; Brodie and Niven, 2000, Grace and MacBride-
Stewart, 2007), it has not been used in randomised, cross-over, double-blind protocols to assess 
the antinociceptive efficacy of drugs in alleviating dysmenorrhoea. The reason for their lack of 
use in dysmenorrhoeic studies is because they are time-consuming and difficult to administer. 
However, in women with dysmenorrhoea, assessment of quality of pain, and assessment of the 
antinociceptive efficacy of drugs, should not be neglected. Implementation of the MPQ allows 
assessment of pain intensity (via the PRI and PPI) and also pain quality (via the words selected), 
but whether there is a correlation between the PRI, PPI and VAS, as measures of pain intensity, 
still needs to be investigated in the same group of women.       
        
3.3. Behavioural measures of pain 
 
Patients who have painful conditions such as fibromyalgia, lower back pain, osteo-arthritis and 
dysmenorrhoea report decreased physical and functional activity levels (Fordyce et al., 1981; 
Krsnich-Shriwise, 1997; Shih et al., 2002; French, 2005). Behaviour rating scales, physical 
activity questionnaires and activity recall diaries are methods used widely for the assessment of 
physical activity (Aaron et al., 1995; Bernstein et al., 1998), and provide information on how pain 
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interferes with the performance of everyday tasks. Women experiencing dysmenorrhoea 
subjectively report decreased physical activity levels and decreased participation in sporting 
events (Andersch and Milsom, 1982; Sundell et al., 1990; Banikram et al., 2000; Tangchai et al., 
2004). In questionnaire and retrospective surveys, women listed menstrual symptoms such as 
dysmenorrhoea, fatigue, fluid retention and weight gain as limiting factors on sports activity and 
performance (Bale and Davis, 1983; Bale and Nelson, 1985; Lebrun, 1993).  
 
Many studies have investigated the effect of menstrual cycle phase (follicular phase versus luteal 
phase) on exercise performance in laboratory-based protocols (Lebrun, 1993; Janse de Jonge, 
2003). Of these studies, few investigators documented significant changes in measures of athletic 
performance as a function of timing of testing during the menstrual cycle (Lebrun, 1993, Janse de 
Jonge, 2003). In the studies that did find differences in athletic performance across the menstrual 
cycle, some measures of athletic performance were found to be decreased in the luteal phase, 
compared to the follicular phase (Lebrun, 1993; Lebrun et al., 1995; Janse de Jonge, 2003). 
However, although some of these studies investigated measures of exercise performance in the 
early follicular phase (e.g., day 3 to day 8), the women were not experiencing moderate-to-severe 
menstrual pain. There have been no studies, to my knowledge, that have investigated whether 
exercise performance, measured objectively using standard exercise tests in a laboratory setting, 
is decreased in women experiencing moderate-to-severe menstrual pain compared to later in the 
follicular phase when the women are not menstruating. So it is not known whether the decrease 
in exercise performance reported by women with moderate-to-severe dysmenorrhoea, in 
questionnaire and retrospective surveys, can be quantified using standard exercise tests in a 
laboratory setting.  
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Despite their ease of administration, behaviour rating scales, questionnaires and recall diaries are 
used to measure a phenomenon, activity, which, unlike pain, is not subjective, and, because of 
low subject compliance, often are inaccurate (Conway et al., 2002). Subjects are likely to recall 
vigorous, structured activity with a high degree of accuracy, but are not as accurate when 
recalling frequent, moderate-intensity activities such as walking (Bassett et al, 2000). Walking is 
the major contributor to physical activity in normal life (Meijer et al., 1991; Levine et al., 2001). 
Another limitation of questionnaires and recall diaries is that reporting of physical activity 
performed may be influenced by the perceived desirability of a given response (Klesges et al., 
1990), as well as inaccurate perception of activity behaviour (Freedson and Miller, 2000).   
An alternative to the questionnaires and diaries, not requiring the same degree of compliance, is 
the assessment of activity via activity data loggers (Puyau et al., 2004). Activity data loggers 
allow for an objective assessment of physical activity, and are particularly useful outside the 
laboratory setting, in free-living people. They are unobtrusive, do not impede movement, and are 
compatible with most daily activities (Mathie et al., 2004; Welk et al., 2004). Furthermore, 
activity data loggers are a valid and reliable tool for the measurement of dynamic physical 
activities, such as walking and running (Esliger and Tremblay, 2006). In patients experiencing 
pain, actigraphy is emerging as a useful tool to measure the debilitating effects of the pain (Kop 
et al., 2005; Long et al., 2008). Actigraphy has been used to show a decrease in physical activity 
in patients with tension-type headache (Kikuchi et al., 2007), women with fibromyalgia (Korzun 
et al., 2002; Kop et al., 2005), and in adolescents with chronic pain (Long et al., 2008). In women 
with fibromyalgia, physical activity levels were recorded more accurately using ambulatory 
activity monitoring as compared with retrospective self-report (Korzun et al., 2002). However, in 
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patients with painful conditions characterized by subjective reports of decreased physical activity, 
such as dysmenorrhoea, research needs to be done to determine whether activity data loggers are 
able to detect the decrease in activity and, if so, whether they can be used to quantify the pain-
reduced decrease in physical activity.  
 
4. Treatment of primary dysmenorrhoea 
 
Despite progress in understanding the pathophysiology of dysmenorrhoea and the availability of 
effective treatments, many women with dysmenorrhoea do not seek medical advice or are under-
treated (Harel, 2002). In a study of 182 twelve to eighteen year-old girls in the United States, 
Johnston (1988), noted a surprising lack of knowledge among adolescent girls as to effective 
treatment for dysmenorrhoea. Only half of the girls knew that certain medications could be taken 
to relieve their pain, and less than one third could name a non-steroidal anti-inflammatory drug 
(NSAID) other than aspirin. A recent study (Tangchai et al., 2004) showed that university 
students from Thailand also were ignorant about the pharmacological treatment of 
dysmenorrhoea. Almost all of these students listed acetaminophen as their treatment drug of 
choice, and indicated that they were dissatisfied with their pain relief. Less than 6% of the 
students knew that the NSAIDs mefenamic acid and ibuprofen were effective in treating 
dysmenorrhoea. The self-care strategies of Taiwanese girls with primary dysmenorrhoea included 
reduced physical activity, herbal remedies, complementary therapies such as heat, and expressing 
emotions (Chen et al., 2006). As a result of these ineffective self-care strategies for 
dysmenorrhoea, poorly treated menstrual pain was the leading cause of recurrent short-term 
school absenteeism among these girls (Chen et al., 2006). The only data to show a group of 
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women satisfied with their self-management of menstrual pain was obtained from a group of 
nurses who, based on their medical training and pharmacological knowledge, were self-
medicating with appropriate NSAIDs (Hewson and van den Akker, 1996). In addition, recent 
studies have shown that many girls are unaware of the causes dysmenorrhoea (Sharma and 
Gupta, 2003; Houston et al., 2006), and therefore do not seek medical advice for their 
dysmenorrhoea (Banikarim et al., 2000). Often adolescent girls and young women fear that a 
medical consultation by a general practitioner or gynaecologist may reveal them to be different or 
abnormal from their peers (Malonne and van Hoek, 2003). In their study on a large group of 
Australian students, Hillen et al (1999) reported that less than 20% of the students with 
dysmenorrhoea had consulted a doctor or nurse about their pain. This low rate is consistent with 
previous studies (Andersch and Milsom, 1982; Wilson and Keye, 1989). More importantly, one 
fifth of the girls whose schooling was affected every, or mostly every, month by menstrual pain 
never had consulted a doctor or nurse for their menstrual pain (Hillen et al., 1999).  
 
Therefore, while the medical profession has advanced in its understanding of the aetiology and 
treatment of dysmenorrhoea, many women still seem to believe that painful menstruation is a 
normal female experience (Johnson, 1988; Wilson and Keye, 1989). Recurrent uterine ischaemia, 
as would occur in untreated dysmenorrhoea, could result in changes in primary afferent output, 
which is known as peripheral sensitisation, as well as changes in dorsal horn activity, which is 
termed central sensitisation (Woolf, 2004). Both of these processes contribute to the enhanced 
responsiveness to noxious stimuli, a process known as hyperalgesia (Woolf, 2004).  Furthermore, 
central sensitisation contributes to the sensation of pain in uninjured tissues during hyperalgesia 
(Mitchell, 1999) which, in untreated women with dysmenorrhoea, could present in later years as 
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chronic pelvic pain of unknown aetiology, or even musculoskeletal pain characteristic of 
fibromyalgia (Giamberardino et al., 1997). Indeed, recurrent painful conditions are known to alter 
the processing of pain within the CNS (Hermann et al., 2008) and dysmenorrhoea has been 
classified as a member of the central sensitivity syndromes (CSS); a group of syndromes 
characterised by central sensitivity (Yunus, 2007). Central sensitivity is defined as an “abnormal 
and intense enhancement of pain by mechanisms in the CNS” (Woolf, 2004). This heightened 
excitability of the nociceptive neurons, not only increases their sensitivity to inputs from afferents 
from the damaged or inflamed site, but also to other convergent inputs (Woolf, 2004). 
 
The two groups of drugs which are effective in the treatment of primary dysmenorrhoea are 
cycloxygenase inhibitors and oral contraceptives (Dawood, 1985; French, 2005; Dawood, 2006).  
 
 
4.1. Oral contraceptives  
 
The efficacy of oral contraceptives in treating dysmenorrhoea can be attributed to decreased 
uterine contractility (Kido et al., 2007). As shown by cine and static magnetic resonance imaging 
(MRI), myometrial activity during menstruation was suppressed in oral contraceptive users 
compared to those not taking oral contraceptives (Kido et al., 2007). The recognition that there is 
an association between dysmenorrhoea and ovulation led to the use of hormonal ovulation 
suppression therapy for the treatment of dysmenorrhoea (Dawood, 1981; Dawood, 2006).  The 
synthetic hormones in oral contraceptives have an impact on endometrial development; they 
suppress ovulation and reduce the thickness of the endometrial lining of the uterus (Dawood, 
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2006). As a result, the volume of menstrual fluid and prostaglandin synthesis both are reduced 
(Dawood, 2006). The decreased production of prostaglandins and subsequent decrease in 
contraction of the myometrium decreases uterine ischaemia and pain (Proctor et al., 2001).  
 
Low-dose oral contraceptives effectively treat dysmenorrhoea. In an open trial of 661women, 
63% experienced dysmenorrhoea pre-treatment, but after a year of hormonal therapy only 12% 
still experienced dysmenorrhoea (Gauthier, 1992). In a much larger open clinical trial of a low-
dose oral contraceptive involving 100 000 women, 65% of the women who experienced 
dysmenorrhoea gained relief (Brill et al., 1991). More recent studies using low-dose oral 
contraceptives as a treatment for dysmenorrhoea concur with these clinical trials. In a 
randomised, double-blind, placebo-controlled study assessing the efficacy and safety of a low-
dose oral contraceptive  in relieving menstrual pain in 77 women with dysmenorrhoea, the oral 
contraceptive significantly reduced the severity of the menstrual pain after the second month of 
administration (Hendrix and Alexander, 2002). Furthermore, the women who received the oral 
contraceptive lost no time from school or work during their third and fourth menstrual cycles 
(Hendrix and Alexander, 2002), and did not report adverse side-effects. Davis et al (2005), in a 
similar type of study, concluded that the use of an oral contraceptive improved both objective and 
subjective measures of pain in 76 adolescent girls. By the third month of oral contraceptive use, 
the girls rated their worst pain as significantly less, and used fewer pain medications than did 
girls taking placebo (Davies et al., 2005).  
 
Even though recent studies have shown low-dose oral contraceptives to be superior to placebo in 
treating dysmenorrhoea, there is still a need for studies or clinical trials to compare the efficacy of 
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oral contraceptives with other popular pharmacological treatments such as NSAIDs (Proctor et 
al., 2001). Even then, if they have equal efficacy, oral contraceptives obviously are not suited to 
women who are planning a pregnancy or for women who do not want to use contraception for 
other reasons. Furthermore, there is the perception held by many parents or guardians that access 
to oral contraceptives in adolescent girls might encourage adolescent sexual behaviour (Davis et 
al., 2006).  
 
4.2. Cycloxygenase inhibitors  
 
4.2.1. Introduction  
 
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the COX enzyme, leading to a reduction 
in prostaglandin production (Figure 3). NSAIDs are the best-established initial therapy for 
primary dysmenorrhoea (Proctor and Farquhar, 2002; Dawood, 2006; Harel, 2006). By 
decreasing prostaglandins, especially PGF2 alpha, there is less vigorous contraction of the uterus, 
less ischaemia, and therefore less pain.  
 
NSAIDs can be classified according to their chemical structure; however, as suggested by Frolich 
(1997), such a chemical classification does not allow us to predict their relative inhibition of the 
COX enzymes. Ratios obtained by the human whole blood assay, which measures inhibition of 
COX-1 in platelets and COX-2 in mononuclear cells stimulated with lipopolysaccharide, now are 
generally accepted as the best reflection of the inhibitory capacity of the drugs in humans 
(Patrignani et al., 1994).  Based on their inhibitory activity on COX-1 and COX-2, there are four 
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main broad groups of NSAIDs: selective COX-1 inhibitors, non-selective COX-inhibitors, 
selective COX-2 inhibitors and specific COX-2 inhibitors (Frolich, 1997; Warner et al., 1999).  
Figure 4 is a representation of some commonly used NSAIDs and their relative selectivity for 
COX-1 and COX-2. Selective COX-1 inhibitors inhibit COX-1 and COX-2 with preference 
towards COX-1. Non-selective COX inhibitors inhibit both COX-1 and COX-2 without 
selectivity for either of the enzymes. Selective COX-2 inhibitors inhibit both COX-1 and COX-2, 
with preference towards COX-2. Specific COX-2 inhibitors are able to inhibit COX-2 strongly 
with only weak activity against COX-1. 
 
When NSAIDs are grouped according to their ability, or selectivity, to inhibit COX-1 and COX-2 
(Figure 4), the prediction of major therapeutic effects and side-effects is possible (Frolich, 1997). 
For example, the NSAID ketorolac, an acetic acid derivative, has a greater selectivity for COX-1 
than etodolac, an NSAID with a similar chemical structure, but with greater selectivity for COX-
2 (Warner et al., 1999). Therefore, compared to etodolac, administration of ketorolac has a 
greater risk of causing gastro-intestinal side-effects because of inhibition of PGI2, the COX-1 
dependent prostaglandin which affords cyto-protection to the gastric mucosa (Lanza, 1981; 
Warner et al., 1999).   
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Figure 4. Commonly used NSAIDs and their relative selectivity for COX-1 and COX-2. Figure adapted  
from Warner et al., 1999.  COX-1 = cycloxygenase-1; COX-2 = cycloxygenase-2. 
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4.2.2. Conventional NSAIDs in primary dysmenorrhoea 
 
Historically, before the development of the selective and specific COX-2 inhibitors, conventional 
NSAIDs such as the selective COX-1 inhibitors (eg., naproxen, ibuprofen, aspirin and 
indomethacin), and the non-selective COX inhibitors (eg., piroxicam, mefenamic acid and 
diclofenac) were prescribed to treat dysmenorrhoea (Marjoribanks et al., 2003; Dawood, 2006; 
Harel, 2006) with varying degrees of success. Many studies and clinical trials have investigated 
the efficacy and safety of the conventional NSAIDs in treating dysmenorrhoea (Marjoribanks et 
al., 2003). Examples of the major studies which have been done to compare the efficacy of 
common conventional NSAIDs with that of placebo, are shown in Table 1, and the studies 
comparing the efficacy of two different conventional NSAIDs in the treatment of primary 
dysmenorrhoea, are shown in Table 2.  
 
The studies listed in Tables 1 and 2 all were randomised, cross-over and double-blind protocols, 
and the women investigated were experiencing menstrual pain resulting from primary 
dysmenorrhoea, and not from pathological conditions characteristic of secondary dysmenorrhoea. 
Furthermore, the women in the studies were not breast-feeding, had regular and normal-length 
menstrual cycles, and were not using hormonal therapy or intrauterine contraceptive devices. 
Analgesic efficacy of the NSAIDs or placebo treatment was assessed by the outcome measures of 
pain relief, requirements for additional medication, restrictions of daily activities, and absence 
from school or work. Most studies measured pain relief by asking the women to rate their 
intensity of pain using verbal and numerical scales; these values then were used to calculate the 
pain-relieving efficacy of the medication. In some of the studies, the pain-relieving efficacy of 
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the medication was calculated as the time-weighted sum of pain intensity difference (SPID) at 6 
or 8 hours after the first dose (SPID-6 and SPID-8). In this calculation, the pain intensity (PI) at 
baseline, before any medication, and then at regular time intervals up to 12 hours after the first 
dose of medication, is measured using a 4-or-5-point numerical scale. The pain intensity 
difference (PID) then is calculated at each post-dose assessment time point by subtracting the PI 
at that time point from the baseline (before medication) PI. The SPID-6 or SPID-8 then is 
calculated for each day of drug administration. The pain-relieving efficacy of the medication, for 
each day, also can be expressed as the total time-weighted pain relief from 0-to-6 or 8 hours after 
the initial dose (TOTPAR-6 or TOTPAR-8). In this calculation, the patient is required to indicate 
their pain relief, at different time points during the day, using a 5 point categorical scale. The 
TOTPAR-6 or TOTPAR-8 then is calculated as the sum (total) of these values at each time point 
up to 6 or 8 hours after the initial dose. In other studies, the analgesic efficacy of the medication 
was expressed as the number of women reporting moderate-to-excellent pain relief, or as the 
number of menstrual cycles where the treatment gave moderate-to-good pain relief. Only two of 
the studies listed in Table 1 and 2 used the VAS to assess the intensity of dysmenorrhoea. None 
of the studies used the MPQ or the DDS to measure the multidimensional nature of pain. Some of 
the studies used questionnaires to assess the detrimental impact of the dysmenorrhoea on normal 
daily activities and ability to go to work, but none of the studies used activity data loggers, or 
other objective measures of physical activity, to quantify the pain-related changes in physical 
behaviour. 
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Table 1.  The efficacy of common conventional NSAIDs versus placebo in treating dysmenorrhoea  
 
 
Comparison Study Number    
of women 
Dose Duration Outcome measure NSAID Placebo Statistical 
significance 
aceclofenac 
vs 
placebo 
 
Letzel et al. 
2006 
81 100mg 
(1 x day) 
2 menstrual 
cycles per 
drug  
SPID-8 
(0-80mm VAS) 
 
LS mean (95% CI) 
241(204,278) 172(136,208) P=0.008 
 
aceclofenac>placebo 
     TOTPAR-8 
(0-80mm VAS) 
 
LS mean (95% CI) 
463(404,521) 367(312423) P=0.019 
 
aceclofenac>placebo 
aspirin 
vs 
placebo 
Kajanoja 
1978 
45 650mg 
(4 x day) 
2 menstrual 
cycles per 
drug 
Number of cycles 
where treatment gave 
moderate/good relief 
(4 point verbal scale) 
13/90 9/90 NS 
diclofenac 
vs 
placebo 
Riihiluoma et 
al. 1981 
35 25mg 
(3 x day) 
2 menstrual 
cycles per 
drug 
Number of cycles 
when pain much 
improved 
(6 point scale) 
34/70 3/70 P<0.05 
 
diclofenac>placebo 
etodolac 
vs 
placebo 
De Souza et 
al. 1991 
40 200mg 
(2 x day) 
1 menstrual 
cycle per 
drug 
Number of women 
reporting moderate or 
excellent pain relief 
(5 point verbal scale)  
28/40 14/40 P<0.005 
 
etodolac>placebo 
flufenamic acid 
vs 
placebo 
Kapadia and 
Elder 1978 
44 200mg 
(3 x day) 
2 menstrual 
cycles per 
drug 
Pain relief score  
(4 point scale)  
 
mean (SD) 
6 (3)  1.5 (2) 
 
P<0.001 
 
flufenamic>placebo 
ibuprofen 
vs 
placebo 
Dawood 
1999 
86 400mg 
(every 4h ) 
1 menstrual 
cycle per 
drug 
Number of women 
reporting 
good/excellent efficacy 
(4 point verbal scale) 
39/86 14/86 Not reported 
SPID-8=sum of time-weighted pain intensity difference scores up to 8h; TOTPAR-8= sum of time-weighted total pain relief scores up to 8h; 
NS=not significant; LS=least squares; CI=confidence interval; VAS=visual analogue scale; SD=standard deviation; Note: outcome measure 
after 1st day of drug administration 
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Table 1 continued 
Comparison Study Number    
of women 
Dose Duration Outcome measure NSAID Placebo Statistical 
significance 
ketoprofen 
vs 
placebo 
Mehlisch 
1990 
60 500mg 
loading 
dose, then 
250 mg (4 x 
day) 
1 menstrual 
cycle per 
drug 
Number of women 
rating efficacy as 
good/excellent after 
1st  dose 
(5 point scale) 
28/60 11/60 P<0.05 
 
ketoprofen>placebo 
ketoprofen 
vs 
placebo 
Gleeson and 
Sorbie 
1983 
31 Dose not 
given 
(every 4-6 h) 
1 menstrual 
cycle per 
drug  
Number of women 
with at least moderate 
pain relief 
(1-10 point scale)   
22/27 10/27 P<0.001 
 
ketoprofen>placebo 
naproxen 
vs 
placebo 
Chan et al. 
1983 
12 550mg 
loading 
dose, then 
275mg (4 x 
day) 
1 menstrual 
cycle per 
drug 
Number of women 
with at least moderate 
pain relief 
(4 point verbal scale)  
11/12 2/12 P<0.01 
 
naproxen>placebo 
naproxen 
vs 
placebo 
 
 
 
Dawood 
1999 
97 550mg 
loading 
dose, then 
275mg 
(every 4 h as 
needed) 
1 menstrual 
cycle per 
drug 
Number of women 
rating treatment very 
good or excellent 
(4 point verbal scale) 
25/97 10/97 Not reported 
naproxen 
vs 
placebo 
Hamann 
1980 
30 500mg 
loading 
dose,then 
250mg as 
needed 
1 menstrual 
cycle per 
drug 
Number of women 
reporting relief of 
cramping 
23/30 5/30 P=0.0006 
 
naproxen>placebo 
naproxen 
vs 
placebo 
Jacobson et al. 
1983 
39 500mg 
loading 
dose, then 
250mg 
(every 4-6 h) 
1 menstrual 
cycle per 
drug 
Number of women 
with at least moderate 
relief 
(5 point scale) 
25/39 0/39 P=0.0005 
 
naproxen>placebo 
  
Note: outcome measure after 1st day of drug administration 
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Table 1 continued 
Comparison Study Number    
of women 
Dose Duration Outcome measure NSAID Placebo Statistical 
significance 
naproxen 
vs 
placebo 
Mehlisch 
1990 
36 500mg 
loading dose, 
250mg (4 x 
day) 
1 menstrual 
cycle per 
drug 
Number of women 
rating efficacy as 
good/excellent after 
1st dose 
(5 point scale) 
22/36 11/36 P<0.05 
 
naproxen>placebo 
naproxen 
vs 
placebo 
Mehlisch and 
Fulmer 
1997 
51 550mg 
loading dose, 
275mg (4 x 
day) 
1 menstrual 
cycle per 
drug 
SPID-6 
(5 point scale) 
 
mean (SE) 
7 (2) 3(2) P<0.001 
 
naproxen>placebo 
     TOTPAR-6 
(5 point scale) 
 
mean (SE) 
12(2) 3(1) P<0.001 
 
naproxen>placebo 
paracetamol 
vs 
placebo 
Dawood and 
Khan-
Dawood 
2007 
12 500mg 
(2 x daily for 
3 days) 
1 menstrual 
cycle per 
drug 
Number of women 
who rated pain relief 
as good 
(4 point verbal scale)  
6/12 3/12 P=0.022 
 
paracetamol>placebo 
piroxicam 
vs 
placebo 
Wilhelmsson 
et al. 
1985 
23 20mg (2 
tablets a day 
for 2 days 
then 1 x day) 
1 menstrual 
cycle per 
drug 
Number of women 
with good or very 
good pain relief 
(5 point scale) 
18/23 5/23 P<0.001 
 
piroxicam>placebo 
 
TOTPAR-6=sum of time-weighted total pain relief scores up to 6h; SPID-6=sum of time-weighted pain intensity difference scores up to 6h; 
SE=standard error; Note: outcome measure after 1st day of drug administration 
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Table 2.  Comparison of the efficacy of common conventional NSAIDs in treating dysmenorrhoea  
 
 
NSAID 1 NSAID 2 Study Number 
of 
women 
Duration Outcome measure NSAID 1 NSAID 2 Statistical 
significance 
aceclofenac 
100mg (1x day) 
naproxen 
500mg 
Letzel et al. 
2006 
91 1 menstrual 
cycle per 
drug 
SPID-8 
 (0-80mm VAS) 
 
LS mean (95% CI)  
241(204,278) 233(197,270) NS 
     TOTPAR-8 
(0-80mm VAS) 
 
LS mean (95% CI) 
463(404,521) 493(437,549) NS 
aspirin 
500mg (3 x day) 
indomethacin 
25 mg (3 x day) 
Kajanoja 
1978 
47 1 menstrual 
cycle per 
drug 
Number of cycles 
where treatment 
gave 
moderate/good 
relief 
(5 point scale) 
13/89 42/90 P<0.001 
 
indomethacin>aspirin 
bromfenac 
50mg per day 
naproxen  
550mg loading 
dose, then 
275mg per day 
Mehlisch 
and Fulmer 
1997 
52 1 menstrual 
cycle per 
drug 
SPID-8 
(5 point scale) 
 
mean (SE) 
6 (1) 7(1.5) NS 
ibuprofen 
400mg (every 4 
h) 
piroxicam 
(20 or 40mg 
daily) 
Dawood 
1999 
87 1 menstrual 
cycle per 
drug 
Number of women 
rating efficacy as  
very good/excellent 
(5 point scale)  
39/87 41/87 NS 
ibuprofen 
400mg (4 x day) 
diclofenac 
50 mg (4 x day) 
Marchini et 
al. 
1995 
60 1 menstrual 
cycle per 
drug 
Number of women 
rating efficacy as  
very good/excellent 
33/60 37/60 NS 
 
TOTPAR-8=sum of time-weighted total pain relief scores up to 8h; SPID-8=sum of time-weighted pain intensity difference scores up to 8h; 
LS=least squares; CI=confidence interval; SE=standard error; NS=not significant; VAS=visual analogue scale. Note: outcome measure after 
1st day of drug administration 
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Table 2 continued 
 
NSAID 1 NSAID 2 Study Number 
of 
women 
Duration Outcome measure NSAID 1 NSAID 2 Statistical 
significance 
naproxen 
250mg-1250mg 
diclofenac 
50-150mg 
Ingemanson 
and 
Sikstrom 
1984 
28 1 menstrual 
cycle per 
drug 
Mean duration (h) 
of pain relief 
(5 point scale) 
 
Mean (± SE) 
4.3 (0.51) 4.4 (0.45) NS 
naproxen 
250mg (4 x day) 
diflunisal 
250mg (4x day) 
Kajanoja 
and Kauste 
1984 
19 1 menstrual 
cycle per 
drug 
Number of cycles 
where treatment 
gave 
moderate/good 
relief 
(5 point scale) 
34/38 28/38 NS 
naproxen 
500mg (2 x day) 
flurbiprofen 
100mg (2 x day 
as needed) 
Andersch 
and Milsom 
1988 
60 1 menstrual 
cycle per 
drug 
Number of women 
with < 2 point pain 
relief 
(5 point scale)  
6/60 8/60 NS 
naproxen 
500mg (2 x day) 
flurbiprofen 
100mg (2 x day 
as needed) 
Andersch 
and Milsom 
1988 
60 1 menstrual 
cycle per 
drug 
Additional 
analgesics required 
5/60 8/60 NS 
naproxen 
250mg (2 x day) 
ibuprofen 
400mg (3 x day) 
Milsom and 
Andersch 
1985 
60 1 menstrual 
cycle per 
drug 
Pain relief score 
after first dose 
(5 point scale) 
 
mean (SE) 
2.3 (0.1) 2.2(0.1) NS 
naproxen 
250mg (2 x day) 
ibuprofen 
400mg (3 x day) 
Milsom and 
Andersch 
1985 
60 1 menstrual 
cycle per 
drug 
Number of women 
absent from work 
6/57 8/57 NS 
 
NS=not significant; SE=standard error; Note: outcome measure after 1st day of drug administration 
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Table 2 continued 
 
NSAID 1 NSAID 2 Study Number    
of 
women 
Duration Outcome measure NSAID 1 NSAID 2 Statistical 
significance 
naproxen  
400mg per day 
acetaminophen 
1000mg per day 
Milsom et 
al. 2002 
81 1 menstrual 
cycle per 
drug 
Pain relief at three 
hours 
(4 point scale) 
 
mean (SD) 
2.2 (1.5) 2.0 (1.5) NS 
naproxen  
400mg per day 
ibuprofen 
200mg (2 x day) 
Milsom et 
al. 2002 
77 1 menstrual 
cycle per 
drug 
Pain relief at three 
hours 
(4 point scale) 
 
mean (SD) 
2.2 (1.5) 1.75(1.5) P<0.001 
 
naproxen>ibuprofen 
naproxen 
275mg (every 4 h 
as needed) 
piroxicam 
 20 or 40mg 
daily 
Dawood  
1999 
87 1 menstrual 
cycle per 
drug 
Number of women 
with very 
good/excellent pain 
relief 
(5 point scale) 
25/87 33/87 Not given 
naproxen 
275mg (every 4 h 
as needed) 
piroxicam 
 20 or 40mg 
daily 
Dawood  
1999 
97 1 menstrual 
cycle per 
drug 
Additional 
analgesics required 
10/97 10/97 NS 
naproxen 
100mg per day 
piroxicam 
40 mg per day 
Wilhelmsson 
et al. 
1985 
69 1 menstrual 
cycle per 
drug 
Number of women 
rating day 1 
treatment as good 
or very good 
(5 point scale) 
45/69 49/69 NS 
naproxen 
500mg loading 
dose, then 250mg 
(4 x day) 
ketoprofen 
(25mg, 50mg or 
70mg loading 
dose, then 25mg 
(4 x day) 
Mehlisch 
1990 
36 1 menstrual 
cycle per 
drug 
Number of women 
rating efficacy as 
good/excellent after 
1st dose  
(5 point scale) 
22/36 28/36 NS 
 
NS=not significant; SD=standard deviation; Note: outcome measure after 1st day of drug administration 
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As seen in Table 1, with the exception of a study investigating the efficacy of aspirin versus 
placebo, conventional NSAIDs were significantly more effective than placebo in treating 
dysmenorrhoea. Although placebo was not as effective in alleviating the menstrual pain, there is 
strong evidence of a placebo effect in many of the women, which is not an uncommon event. In 
studies of anti-nociception in which subjects have an expectation of pain relief, placebo 
treatments invariably are effective at least in some patients, irrespective of the aetiology of the 
pain; placebo analgesia is mediated by endogenous opioids (Benedetti et al., 2003). Indeed 
previous investigations of efficacy of pharmaceutical management of dysmenorrhoea have 
reported that 15-33% of patients with primary dysmenorrhoea responded favourably to placebo 
administration (Fedele et al., 1989).  
 
When the pain-relieving ability of two conventional NSAIDs was compared (Table 2), most 
studies found no statistically significant differences between them. The exception were studies 
which found aspirin to be significantly less effective than indomethacin (Kajanoja, 1978), and 
ibuprofen less effective than naproxen (Milsom et al., 2002).  
 
Conventional NSAIDs therefore are better than placebo in treating primary dysmenorrhoea, 
though women taking them need to be aware that they may cause gastrointestinal complications 
such as gastric ulcers, indigestion and nausea (see 4.2.4.1.). It is therefore not surprising that 
when the more COX-2 selective inhibitors were developed in 1999, they were vigorously 
marketed for their ability to treat dysmenorrhoea, via COX-2 inhibition, and to spare COX-1, 
which decreased their gastrointestinal side-effects.  
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4.2.3. Selective COX-2 and specific COX-2 inhibitors in primary dysmenorrhoea 
 
Since their development in 1999, the selective COX-2 inhibitor celecoxib and the specific COX-2 
inhibitor rofecoxib have been marketed for treating dysmenorrhoea. When their selectivity is 
estimated by the human whole blood assay, celecoxib has a selectivity of 7.6 and rofecoxib a 
selectivity of 35 in favour of COX-2 (Riendeau et al., 2001). More recently, second-generation 
specific COX-2 inhibitors, with higher selectivity for COX-2, have been developed and marketed 
for treating dysmenorrhoea. For example, valdecoxib, the successor to celecoxib, has a selectivity 
of 30, and etoricoxib, the successor to rofecoxib, has a selectivity of 106 in favour of COX-2 
(Riendeau et al., 2001). Table 3 is a summary of the studies which have investigated the efficacy 
of the selective and specific COX-2 inhibitors, versus placebo, in alleviating dysmenorrhoea. 
Table 4 is a summary of the studies investigating the efficacy of the selective COX-2 and 
specific COX-2 inhibitors versus either naproxen sodium, a selective COX-1 inhibitor, or 
mefenamic acid, a non-selective COX inhibitor, or versus other specific COX-2 inhibitors, in 
alleviating dysmenorrhoea. As with the studies shown in Table 1 and 2, the studies listed in 
Tables 3 and 4 all were randomised, cross-over and double-blind protocols, and the women 
investigated were experiencing menstrual pain resulting from primary dysmenorrhoea, and not 
from pathological conditions characteristic of secondary dysmenorrhoea. Analgesic efficacies of 
the specific COX-2 inhibitors or placebo treatment were assessed by the outcome measures of 
pain relief and requirements for additional medication. All of the studies listed in Table 3 and 4 
measured pain relief by asking the women to rate their intensity of pain using verbal and 
numerical scales; these values then were used to calculate the pain-relieving efficacy of the 
medication. In almost all of the studies, the pain-reliving efficacy of the medication was 
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calculated as the time-weighted sum of pain intensity difference (SPID) at 8 hours after the first 
dose (SPID-8), or as the total time-weighted pain relief 8 hours after the first dose (TOTPAR-8).    
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Table 3.  The efficacy of selective COX-2 and specific COX-2 inhibitors, versus placebo, in treating dysmenorrhoea  
 
 
Comparison Study Number    
of women 
Dose  Duration Outcome measure NSAID Placebo Statistical 
significance 
etoricoxib  
vs 
placebo  
Malmstrom et 
al. 
2003 
73 120mg once 
daily 
1 menstrual 
cycle per 
drug 
SPID-8 
(0-4 point scale) 
 
LS mean (95% CI)  
12 (11,13) 8 (6,9) P<0.001 
 
etoricoxib>placebo 
     TOTPAR-8 
(0-4 point scale) 
 
LS mean (95% CI) 
20 (18,22) 13(10,15) P<0.001 
 
etoricoxib>placebo 
     Percentage of 
women who took 
rescue medication 
within 24 hours 
13.4% 44% P<0.001 
 
etoricoxib>placebo 
lumiracoxib 
 vs 
placebo 
Bitner et al. 
2004 
84 400mg 
once daily 
1 menstrual 
cycle per 
drug 
SPID-8 
(0-3 point scale) 
 
mean (SD) 
11 (7) 7 (7) P<0.001 
 
lumiracoxib>placebo 
nimesulide 
vs 
placebo 
Pulkkinen 
1987 
14 100mg 
(2 x day) 
1 menstrual 
cycle per 
drug 
Number of cycles 
were women rated 
therapy good/very 
effective 
(4 point scale) 
22/28 9/27 P<0.01 
 
nimesulide>placebo 
nimesulide 
vs 
placebo 
Rondel et al. 
1984 
12 200mg/ day 1 menstrual 
cycle per 
drug 
Number of cycles 
were women rated 
therapy good/very 
effective 
(5 point scale) 
10/12 2/12 P<0.01 
 
nimesulide>placebo 
 
TOTPAR-8=sum of time-weighted total pain relief scores up to 8h; SPID-8=sum of time-weighted pain intensity difference scores up to 8h; 
LS=least squares; CI=confidence interval; SD=standard deviation; Note: outcome measure after 1st day of drug administration 
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Table 3 continued 
Comparison Study Number    
of women 
Dose Duration Outcome measure NSAID Placebo Statistical 
significance 
rofecoxib 
vs 
placebo 
Sahin et al. 
2003 
55 25mg per 
day 
 
50mg per 
day 
1 menstrual 
cycle per 
drug 
SPID-8 
(0-4 point scale) 
 
mean (SD)    
17 (7)  
(25mg) 
 
21 (4) 
(50mg) 
6 (4) P<0.001 for both 
doses 
 
rofecoxib>placebo 
rofecoxib  
vs 
placebo 
 
Bitner et al. 
2004 
84 50mg once 
daily 
1 menstrual 
cycle per 
drug 
SPID-8 
(0-3 point scale) 
 
Mean (SD) 
11 (8) 7 (7) P<0.001 
 
rofecoxib>placebo 
     Percentage of 
women who rated 
analgesic efficacy 
as good/excellent 
(0-3 point scale) 
62% 28% P<0.001 
 
rofecoxib>placebo 
rofecoxib 
vs 
placebo 
Morrison et al. 
1999 
118 25mg, then 
25mg daily 
as needed 
 
50mg, then 
25mg daily 
as needed  
1 menstrual 
cycle per 
drug 
TOTPAR-8 
(0-32 point scale) 
 
LS mean (95% CI)    
17 (16,19) 
(25/25mg) 
 
 
18 (16,20) 
(50/25mg) 
13 (11,14) P<0.006 for both 
doses 
 
rofecoxib>placebo 
     SPID-8 
(-8 to 24 point 
scale) 
 
LS mean (95% CI)    
10 (9,11) 
(25/25mg) 
 
 
10 (9,11) 
(50/25mg) 
7 (6,8) P<0.006 for both 
doses 
 
rofecoxib>placebo 
 
TOTPAR-8=sum of time-weighted total pain relief scores up to 8h; SPID-8=sum of time-weighted pain intensity difference scores up to 8h; 
LS=least squares; CI=confidence interval; SD=standard deviation; Note: outcome measure after 1st day of drug administration 
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Table 3 continued 
 
Comparison Study Number    
of women 
Dose Duration Outcome measure NSAID Placebo Statistical 
significance 
rofecoxib 
vs 
placebo 
Morrison et al. 
1999 
118 25mg, then 
25mg daily 
as needed 
 
50mg, then 
25mg daily 
as needed  
1 menstrual 
cycle per 
drug 
Subjects (%) who 
took rescue 
medication within 
12 hours 
 
31% 
(25/25mg) 
 
32% 
(50/25mg) 
53% P<0.006 for both 
doses 
 
rofecoxib>placebo 
valdecoxib  
vs 
placebo 
Daniels et al. 
2002 
118 20 and 
40mg (2 x 
per day as 
needed) 
1 menstrual 
cycle per 
drug 
SPID-8 
(0-3 point scale) 
    
10 (20mg) 
 
11 
(40mg) 
7 P<0.01 (20mg) 
 
P<0.001 (40mg) 
 
valdecoxib>placebo 
     TOTPAR-8 
(0-5 point scale) 
 
19 
(20mg) 
 
21 
(40mg) 
15 P<0.01 (20mg) 
 
P<0.001(40mg) 
 
valdecoxib>placebo 
 
TOTPAR-8=sum of time-weighted total pain relief scores up to 8h; SPID-8=sum of time-weighted pain intensity difference scores up to 8h;  
Note: outcome measure after 1st day of drug administration 
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Table 4.  The efficacy of selective COX-2 and specific COX-2 inhibitors versus other NSAIDs in treating dysmenorrhoea  
 
 Comparison Study Number    
of 
women 
Dose 
NSAID 1 
Dose 
NSAID 2 
 
Duration Outcome measure NSAID 1 NSAID 2 Statistical 
significance 
etoricoxib  
vs 
naproxen  
Malmstrom 
et al. 2003 
73 120mg 
once 
daily 
550mg  
bi-daily 
1 menstrual 
cycle per drug 
SPID-8 
(0-4 point scale) 
 
LS mean (95% CI)  
12 (11,13) 13(11,14) P=0.4 (NS) 
      TOTPAR-8 
(0-4 point scale) 
 
LS mean (95% CI) 
20 (18,22) 22(19,24) P=0.3 (NS) 
     
 
 Percentage of 
women who took 
rescue medication 
within 24 hours) 
13% 19% P=0.3 (NS) 
lumiracoxib  
vs 
naproxen  
Bitner et al. 
2004 
84 400mg 
once daily 
500mg  
bi-daily 
1 menstrual 
cycle per drug 
SPID-8 
(0-3 point scale) 
 
Mean (SD) 
9 (7) 11(7) NS 
      Percentage of 
women who rated 
analgesic efficacy as 
good/excellent 
(0-3 point scale) 
50% 52% NS 
lumiracoxib  
vs 
rofecoxib 
Bitner et al. 
2004 
84 400mg 
once daily 
50mg one 
daily 
1 menstrual 
cycle per drug 
SPID-8 
(0-3 point scale) 
 
Mean (SD) 
11 (7) 11(8) NS 
 
TOTPAR-8=sum of time-weighted total pain relief scores up to 8h; SPID-8=sum of time-weighted pain intensity difference scores up to 8h; 
LS=least squares; CI=confidence interval; SD=standard deviation; NS=not significant; Note: outcome measure after 1st day of drug 
administration 
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  Table 4 continued 
Comparison Study Number    
of 
women 
Dose 
NSAID 1 
Dose 
NSAID 2 
 
Duration Outcome measure NSAID 1 NSAID 2 Statistical 
significance 
meloxicam  
vs 
mefenamic 
acid 
 De Mello 
et al. 2004 
114 15mg per 
day 
50mg (3 x 
day) 
1 menstrual 
cycle per drug 
Percentage of 
women who rated 
pain relief as good  
(0-100 mm VAS) 
39% 35% NS 
rofecoxib  
vs 
naproxen  
Sahin et al. 
2003 
55 25mg per 
day 
 
50mg per 
day 
550mg  
bi-daily 
1 menstrual 
cycle per drug 
SPID-8 
(0-4 point scale) 
 
mean (SD)    
17 (7)  
(25mg) 
 
21 (4) 
(50mg) 
18 (6) NS for both 
doses of 
rofecoxib 
rofecoxib  
vs 
naproxen  
Morrison et 
al. 1999 
118 25mg, then 
25mg daily 
as needed 
 
50mg, then 
25mg daily 
as needed 
550mg 
bi-daily 
1 menstrual 
cycle per drug 
TOTPAR-8 
(0-32 point scale) 
 
LS mean (95% CI)     
17 (16,19) 
(25/25mg) 
 
 
18 (16,20) 
(50/25mg) 
18(17,20) 
(25/25mg) 
 
 
 
NS for both 
doses of 
rofecoxib 
      SPID-8 
(-8 to 24 point scale) 
 
LS mean (95% CI)    
10 (9,11) 
(25/25mg) 
 
 
10 (9,11) 
(50/25mg) 
11(10,12) NS for both 
doses of 
rofecoxib 
      Subjects (%) who 
took rescue 
medication within 
12 hours 
 
31% 
(25/25mg) 
 
32% 
(50/25mg) 
30% NS for both 
doses of 
rofecoxib 
 
TOTPAR-8=sum of time-weighted total pain relief scores up to 8h; SPID-8=sum of time-weighted pain intensity difference scores up to 8h;  
VAS=visual analogue scale; LS=least squares; CI=confidence interval; SD=standard deviation; NS=not significant; Note: outcome measure 
after 1st day of drug administration 
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Table 4 continued 
Comparison Study Number    
of 
women 
Dose 
NSAID 1 
Dose 
NSAID 2 
 
Duration Outcome measure NSAID 1 NSAID 2 Statistical 
significance 
valdecoxib 
vs 
naproxen  
Daniels et 
al. 2002 
118 20 and 
40mg (2 x 
per day as 
needed) 
550mg 
bi-daily 
1 menstrual 
cycle per drug 
SPID-8 
(0-3 point scale) 
    
10 (20mg) 
 
11 
(40mg) 
11 NS for both 
doses of 
valdecoxib 
      TOTPAR-8 
(0-5 point scale) 
 
19 
(20mg) 
 
21 
(40mg) 
21 NS for both 
doses of 
valdecoxib 
 
TOTPAR-8=sum of time-weighted total pain relief scores up to 8h; SPID-8=sum of time-weighted pain intensity difference scores up to 8h; 
NS=not significant; Note: outcome measure after 1st day of drug administration 
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As can be seen from Table 3 and Table 4, the analgesic efficacy of the selective COX-2 and 
specific COX-2 inhibitors in alleviating primary dysmenorrhoea was superior to placebo, and 
was comparable to the conventional COX inhibitors, naproxen sodium and mefenamic acid. 
When the specific COX-2 inhibitors were compared head-to-head they were all equally effective 
in treating dysmenorrhoea. If the iso-enzyme involved in generating dysmenorrhoea is COX-2, 
then, theoretically, specific COX-2 inhibitors should offer superior efficacy to a selective COX-1 
inhibitor such as naproxen sodium. However, this was not the case; naproxen sodium was as 
effective as rofecoxib and valdecoxib in attenuating dysmenorrhoea. Selectivity does not 
necessarily imply potency; rofecoxib has a selectivity of 35 in favour of COX-2, but may not be 
as effective as naproxen sodium, a drug with a far lower selectivity for COX-2, in successfully 
inhibiting COX-2. To date, the only selective COX-1 inhibitor with which the specific COX-2 
inhibitors have been compared is naproxen sodium (Table 4). Studies still need to investigate the 
analgesic efficacy, and safety, of other COX-inhibitors, of differing COX-2 specificity, in 
attenuating dysmenorrhoea in the same women.  
 
4.2.4. Side-effects of COX inhibitors  
 
Although useful in the treatment of inflammatory disorders such as osteo-arthritis and 
dysmenorrhoea, NSAIDs do have harmful side-effects (Vane et al., 1998; Botting, 2006; Zhang 
et al., 2006). The side-effects of NSAIDs result at least partially from the inhibition of 
constitutive COX-1 and COX-2, which are needed for synthesis of prostanoids involved in 
homeostatic functions such as gastrointestinal cyto-protection, renal functioning and anti-
thrombosis (Ofmann et al., 2002).  
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4.2.4.1. Side-effects of COX-1 inhibition 
 
The most serious and common side-effect that occurs after administration of NSAIDs which 
inhibit COX-1 is that of gastrointestinal tract irritation, bleeding and ulceration (Lanza, 1989). 
Indeed the stronger inhibitors of COX-1, as shown by Figure 4, such as ketorolac and 
flurbipofen, cause more damage to the stomach than do other NSAIDs because the cyto-
protective role of PGI2 is inhibited (Lanza, 1989). COX-1 inhibition also can cause renal damage 
by inhibiting the formation of the COX-1 dependent PGE2 and PGI2, which are involved in 
regulation of renal blood flow and sodium and water absorption (Schlondorff, 1993; Palmer, 
1995). The unwanted renal effects of these NSAIDs are reduced glomerular filtration rate and 
decreased sodium and water excretion (Schlondorff, 1993; Palmer, 1995).  
 
In studies that investigated the safety, and efficacy of  the conventional NSAIDs (selective COX-
1 inhibitors and non-selective COX inhibitors) compared to placebo, in the treatment of 
dysmenorrhoea, the conventional NSAIDs proved to be significantly more likely to cause 
gastrointestinal or mild neurological adverse effects (odds ratio 7.91, 95% CI 5.65 to 11.9) 
(Marjoribanks et al., 2003). When conventional NSAIDs were compared with each other in the 
Cochrane review, no significant difference was found between them with respect to adverse 
effects (Marjoribanks et al., 2003).  
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4.2.4.2. Side-effects of COX-2 inhibition 
 
The selective and specific COX-2 inhibitors were identified as potent anti-inflammatory drugs 
with low ulcerogenic activity because they preferentially inhibit COX-2 rather than COX-1 
(Warner et al., 1999). However, although safer for the gastrointestinal tract, inhibition of 
constitutive COX-2 does result in unique and potentially dangerous side-effects. 
 
Many clinical trials, comparing the efficacy and safety of specific COX-2 drugs with 
conventional NSAIDs, have been completed (Mitchell and Warner, 2006), all with different 
results. The “Vioxx” Gastrointestinal Research (VIGOR) Trial compared high-dose rofecoxib (50 
mg per day) with standard dose naproxen (500 mg per day) in patients with rheumatoid arthritis 
(Bombardier et al., 2000). Although the specific COX-2 inhibitor rofecoxib decreased the risk of 
gastric complications, the number of myocardial infarctions was increased in the rofecoxib group, 
compared with the selective COX-1 inhibitor naproxen, by five to one (Bombardier et al., 2000). 
At the time, the decreased risk of myocardial infarction in the patients taking naproxen was 
thought to occur because of the anti-thrombotic effect of naproxen via inhibition of the COX-1 
dependent prostanoid, thromboxane (TXA2), and not because of any involvement from rofecoxib 
(Mitchell and Warner, 2006). Adverse cardiovascular side-effects have not been found with the 
other specific COX-2 inhibitors, celecoxib and lumiracoxib. The Celecoxib Long-term Arthritis 
Safety Study (CLASS) trial, which compared the safety of celecoxib, a specific COX-2 inhibitor, 
with the selective COX-1 inhibitor ibuprofen and the non-selective COX inhibitor diclofenac, in 
arthritic patients, showed no increase in thrombotic events (McMurray and Hardy, 2002). More 
recently, the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) 
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compared the gastrointestinal and cardiovascular side-effects of the specific COX-2 inhibitor 
lumiracoxib, with ibuprofen and naproxen (Farkouh et al., 2004). Lumiracoxib caused fewer 
gastrointestinal side-effects than either ibuprofen or naproxen without any increase in 
cardiovascular side-effects (Farkouh et al., 2004). Unfortunately, neither the TARGET nor the 
CLASS trial had a placebo arm, and the cardiovascular risk associated with specific COX-2 
inhibitors continues to be a subject of debate. Recent trials investigating the efficacy of celecoxib 
and rofecoxib in preventing colon adenomas demonstrated a higher incidence of cardiovascular 
events, including myocardial infarction, in the drug-treated group compared to the placebo group 
(Bresalier et al., 2005; Solomon et al., 2005), which lead to the withdrawal of rofecoxib from the 
world market in October 2004 (Botting, 2006). However, rofecoxib was re-instated in February 
2005 with certain restrictions.  
 
In addition to rofecoxib and celecoxib, the new generation specific COX-2 inhibitors, valdecoxib 
and its injectable form, parecoxib, have been associated with a potential increase in thrombotic 
events (Ott et al., 2003), which lead to the withdrawal of valdecoxib from the United States 
market, on recommendation by the FDA, in April 2005. Some researchers have shown that 
laminar shear stress, which is constantly created by the pressure and movement of blood within 
the vessel lumen, up-regulates the COX-2 formation of the anti-thrombotic prostaglandin, PGI2 
(Topper et al., 1996; Inoue et al., 2002). It is quite possible that selective COX-2 inhibitors 
inhibit the constitutive COX-2 enzyme in the endothelium, which is required for the synthesis of 
the anti-thrombotic prostaglandin, PGI2, while the COX-1 enzyme, responsible for the synthesis 
of the pro-thrombotic TXA2 by the platelets, is spared (Topper et al., 1996; McAdam et al., 1999; 
Inoue et al., 2002; Botting, 2006). The net response therefore would be thrombogenesis which 
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could lead to cardiovascular complications (McAdam et al., 1999).  However, other studies have 
shown that shear stress in the blood vessels increases the expression of COX-1 and not COX-2 
(Okahara et al., 1998), and therefore there is no consistent evidence that inhibition of COX-2, and 
therefore PGI2, by specific COX-2 inhibitors is responsible for the cardiovascular side-effects.  
The inhibition of constitutive COX-2 in the kidney by the specific COX-2 drugs could contribute 
to the cardiovascular side-effects of these drugs. In individuals with normal renal function the 
effects of inhibiting COX-2 in the kidney are not associated with blood pressure changes nor 
altered urinary sodium excretion and creatinine clearance (Dilger et al., 2002). Of more concern 
is that in elderly patients, who may have compromised renal function, specific COX-2 inhibitors 
have been shown to decrease glomerular filtration rate and decrease sodium excretion, which 
could account for the oedema and increased blood pressure in these patients (Swan et al., 2000; 
Whelton et al., 2001; Whelton et al., 2002). Therefore, in patients with compromised renal 
function, specific COX-2 inhibitors could result in cardiovascular side-effects. 
 
Regulatory authorities worldwide recommended that specific COX-2 drugs be kept on the 
market, because they produce fewer incidences of gastro-intestinal ulcers than conventional 
NSAIDs, but until proven otherwise, specific COX-2 drugs should carry a boxed warning that 
their use could be associated with an increased risk of cardiovascular events, including 
myocardial infarction or stroke (Okie, 2005). The United States FDA stipulates that specific 
COX-2 inhibitors must not be used in patients with established ischaemic heart disease or 
cerebrovascular disease, and also not in patients with peripheral arterial disease, and should be 
used cautiously in patients with risk factors for heart disease such as hypertension, 
hyperlipidaemia, diabetes and smoking (Botting, 2006). Furthermore, the FDA recommends that 
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healthcare professionals should prescribe the lowest effective dose for the shortest possible 
duration of treatment (Mitchell and Warner, 2006).  
 
Although there was great concern over their potential to cause cardiovascular side-effects such as 
stroke and myocardial infarction, these side-effects are unlikely to occur in young, healthy 
women who are taking the specific COX-2 inhibitors for two to four days every month. 
Certainly, in the four published studies that investigated the analgesic efficacy of the specific 
COX-2 inhibitors in dysmenorrhoea, the specific COX-2 inhibitors rofecoxib, etoricoxib and 
lumiracoxib had an adverse effects profile similar to placebo (Daniels et al., 2002; Malmestrom 
et al., 2003; Bitner et al., 2004; Edwards et al., 2004). In all four studies, the specific COX-2 
inhibitors were well tolerated and did not cause any serious side-effects; the most common side-
effects were nausea, drowsiness and headache, which also occurred in the women receiving 
placebo, and in the women receiving the selective COX-1 inhibitor, naproxen sodium (Daniels et 
al., 2002; Malmestrom et al., 2003; Bitner et al., 2004; Edwards et al., 2004).  
  
Therefore, for an acute but recurrent painful condition such as primary dysmenorrhoea, specific 
COX-2 inhibitors are as effective in alleviating pain as conventional NSAIDs, and are less likely 
to cause gastrointestinal complaints. Certainly, a specific COX-2 inhibitor should be considered 
in women with a history of conventional NSAID gastrointestinal adverse effects, and in women 
with coagulation deficiencies.   
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Thesis aims 
 
The increased production and release of endometrial prostaglandins (PGs), especially PGF2 
alpha, at menstruation causes increased uterine contraction and uterine ischaemia (Dawood, 
2006). Contraction of an ischaemic myometrium causes the menstrual pain. In the endometrium, 
prostaglandin synthesis from arachidonic acid, and other precursors, is catalyzed by iso-enzymes 
of the COX family; COX-1 and COX-2 (Funk, 2001; Botting, 2006). Non-steroidal anti-
inflammatory drugs (NSAIDs) inhibit the COX enzyme, leading to a reduction in prostaglandin 
production (Harel, 2006). NSAIDs are the best-established initial therapy for primary 
dysmenorrhoea; they decrease prostaglandins, especially PGF2 alpha, and therefore cause less 
vigorous contraction of the uterus, less ischaemia, and less pain (Dawood, 2006; Harel, 2006).  
    
Historically, before the development of the selective and specific COX-2 inhibitors, conventional 
NSAIDs, which were selective COX-1 inhibitors, or non-selective COX inhibitors, were 
prescribed to treat dysmenorrhoea, with varying degrees of success, but with a risk of causing 
gastrointestinal side-effects (Lanza, 1989). More recently, the selective COX-2 inhibitors and 
specific COX-2 inhibitors have been shown to be as effective as the conventional NSAIDs in 
alleviating dysmenorrhoea, but with fewer gastrointestinal side-effects (Daniels et al., 2002; 
Edwards et al., 2004). However, no studies have compared the analgesic efficacy of three COX-
inhibitors, covering a spectrum of COX-2 selectivity, in attenuating dysmenorrhoea in the same 
women. In the study which I report in Chapter 2, I investigated the efficacy of a specific COX-2 
inhibitor promoted for treatment of dysmenorrhoea (rofecoxib), a selective COX-2 inhibitor 
(meloxicam, with which specific COX-2 inhibitors have not been compared previously), and a 
 57 
non-selective COX inhibitor (diclofenac potassium), in eleven otherwise-healthy young women 
with primary dysmenorrhoea. I employed a double-blind, cross-over, randomised design, which 
also included a placebo. The women’s intensity of menstrual pain was assessed using two well 
authenticated pain scales; the MPQ and the VAS. The VAS allows only for assessment of pain 
intensity. The MPQ allows for assessment of pain intensity, via the pain response index (PRI) 
and present pain intensity (PPI) index, and assessment of the quality of pain, via the words 
chosen. Therefore, as a secondary aim, I determined if there was a correlation between the pain 
intensity, as assessed by the MPQ, and the pain intensity as measured by the VAS, in the women 
with dysmenorrhoea.  
 
Like patients who have painful conditions such as fibromyalgia, lower back pain and osteo-
arthritis, women with dysmenorrhoea report decreased physical and functional activity (Fordyce 
et al., 1981; Krsnich-Shriwise, 1997; Keen et al., 1999). Behaviour rating scales, physical activity 
questionnaires and activity recall diaries are the most widely-used methods for the assessment of 
physical activity, and can provide subjective information on how pain interferes with the 
performance of everyday tasks. Although women have subjectively reported the detrimental 
impact of moderate-to-severe dysmenorrhoea on sports participation and functional ability 
(Andersch and Milsom, 1982; Sundell et al., 1990; Banikram et al., 2000; Tangchai et al., 2004),   
no studies, to my knowledge, have quantified the decrease in exercise performance, or functional 
ability, in a standardised laboratory protocol. So it is not known to what extent women with 
moderate-to-severe dysmenorrhoea, who do engage in exercise, have reduced exercise or 
functional ability. In the study reported in Chapter 3, I aimed to assess whether dysmenorrhoea 
decreases the exercise performance of healthy women in laboratory exercise performance tests, 
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and, if so, to quantify the decrease in exercise performance. Secondly, I aimed to determine 
whether diclofenac potassium, a non-selective COX inhibitor which had been effective in 
attenuating dysmenorrhoea in my first study, would restore any decreases in the women’s 
exercise performance to levels measured when the women were in a pain-free phase of the 
menstrual cycle. I designed an exercise-testing protocol specifically to test the functional ability 
of the women. They were required to walk uphill on a motorised treadmill at increasing speeds 
and elevation, until exhaustion or pain caused them to stop the test. They also were asked to 
perform a functional activity which I designed to assess their ability to flex at the waist, pick up a 
light weight, and reach up to place the weight on a stand above their head. Furthermore, I used 
standard apparatus to measure their leg press capacity, a measure of leg strength.  
       
I was able to show that dysmenorrhoea indeed does decrease the exercise performance, and 
functional ability of healthy women in laboratory exercise performance tests, and was able to 
quantify the decrease in performance. To follow up, I investigated if I could use decrement in 
activity to quantify, the detrimental impact that dysmenorrhoea has on physical activity during 
everyday life. An alternative to the questionnaires and diaries, generating objective measurement 
of activity without requiring the same degree of compliance, is the assessment of activity, via 
data loggers (actigraphy) attached to the subject (Westerterp, 1999). Activity data loggers allow 
for an objective assessment of physical activity, and are particularly useful outside the laboratory 
setting, in free-living people (Mathie et al., 2004; Welk et al., 2004). In patients experiencing 
pain, actigraphy is emerging as a useful tool to measure the debilitating effects of the pain (Kop 
et al., 2005; Long et al., 2008) or to detect the effects of physical, surgical or pharmacological 
interventions. In the study reported in Chapter 4, I assessed whether a hip-mounted miniature 
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activity data logger was able to quantify the reduced physical activity reported by women with 
primary dysmenorrhoea. Women with a history of primary dysmenorrhoea, and women without a 
history of dysmenorrhoea, wore an activity data logger for three consecutive days starting on the 
first day of menstruation, and, later, for another three consecutive days during the follicular phase 
of their menstrual cycle. For the duration of the study, the women recorded their intensity of 
menstrual pain on a VAS. I included the women without a history of dysmenorrhoea in my study 
to investigate whether menstrual pain, or menstruation itself, was responsible for any decrease in 
physical activity I might observe.  
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The effect of three cycloxygenase inhibitors on intensity of primary 
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ABSTRACT 
 
We quantified the impact of dysmenorrhea on exercise performance, and assessed the analgesic 
efficacy of diclofenac potassium, a non-steroidal anti-inflammatory drug, in alleviating pain and 
restoring exercise performance. Twelve healthy young women, with a history of primary 
dysmenorrhea, completed, in a random order, laboratory exercise-testing sessions when they 
were in the late-follicular pain-free phase of the menstrual cycle, and when they were 
experiencing dysmenorrhea, and receiving, in a double-blind fashion, either 100mg of diclofenac 
potassium or placebo. We assessed the women’s leg strength (1-repetition maximum test), 
aerobic capacity (treadmill walking test) and ability to perform a functional test (task-specific 
test). Compared to placebo, diclofenac potassium significantly decreased dysmenorrhea on the 
day of administration (Visual Analog Scale, P<0.001 at all times). When receiving placebo, the 
women’s performance in the tests was decreased significantly, compared to when they were 
receiving diclofenac potassium (P<0.05), and compared to when they were in the late-follicular 
pain-free phase of the menstrual cycle (P<0.05 for treadmill test, P<0.01 for task-specific test and 
1-repetition maximum test). Diclofenac potassium restored exercise performance to a level not 
different to that achieved in the late-follicular pain-free phase of the menstrual cycle. 
 
Perspective 
In women with primary dysmenorrhea, menstrual pain, if untreated, decreases laboratory-
assessed exercise performance. A recommended daily dose of a readily-available NSAID, 
diclofenac potassium, is effective in relieving menstrual pain, and restoring physical performance 
to levels achieved when the women were in the late-follicular pain-free phase of the menstrual 
cycle. 
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INTRODUCTION 
Primary dysmenorrhea is the cramping pain that women of child-bearing age experience in the 
lower abdomen just before menstruation, or during menstruation, in the absence of any pelvic 
pathology.9, 13, 16  Reported prevalence rates for primary dysmenorrhea are as high as 50 to 90 
percent 23, 28 , with about 15 to 33 percent of women with dysmenorrhea reporting moderate to 
severe menstrual pain.1, 12, 15, 33 The pain is believed to result from excessive prostaglandin (PG) 
release, particularly PGF2 alpha.13, 19  As progesterone concentrations fall before menstruation, 
arachidonic acid is released from the endometrial cell membranes and a cascade of prostaglandin 
synthesis is initiated in the uterus. 19 In comparison to women with eumenorrhea, women with 
dysmenorrhea have higher concentrations of PGF2 alpha in their menstrual fluid. 2, 31  PGF2 alpha 
causes vasoconstriction of uterine blood vessels (uterine ischemia) and increased uterine smooth 
muscle contraction 17, 18 , and it is the contraction of the ischemic uterus that is the likely cause of 
dysmenorrhea.13    
 
The detrimental impact of moderate-to-severe dysmenorrhea on the lives of women is under-
appreciated. In many countries, dysmenorrhea is the leading cause of recurrent short-term school 
and work absenteeism in adolescent girls and women, 5, 25 and it has a negative impact on social, 
academic and sports activities in female adolescents. 5 Women experiencing moderate-to-severe 
dysmenorrhea subjectively report decreased physical activity levels and decreased participation 
in sporting events. 1, 5, 35, 36 In questionnaire and retrospective surveys, women listed menstrual 
symptoms such as dysmenorrhea, fatigue, fluid retention and weight gain as limiting factors on 
sports activity and performance. 3, 4, 27   
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Many studies have investigated the effect of menstrual cycle phase (follicular phase versus luteal 
phase) on exercise performance in laboratory-based protocols. 24, 27 In the studies that did find 
differences in athletic performance across the menstrual cycle, some measures of athletic 
performance were found to be decreased in the luteal phase, compared to the follicular phase. 24, 
27
 However, although some of these studies investigated measures of exercise performance in the 
early follicular phase (e.g., day 3 to day 8 of the menstrual cycle), the women were not 
experiencing moderate-to-severe menstrual pain. There have been no studies, to my knowledge, 
that have investigated whether exercise performance, measured objectively using standard 
exercise tests in a laboratory setting, is decreased in women experiencing moderate-to-severe 
menstrual pain compared to later in the follicular phase when the women are not menstruating. 
So it is not known whether the decrease in exercise performance reported by women with 
moderate-to-severe dysmenorrhoea, in questionnaire and retrospective surveys, can be quantified 
using standard exercise tests in a laboratory setting.  
 
If exercise performance is indeed reduced by the pain, and not by other factors related to 
menstruation, we would expect that treatment of the pain would improve exercise performance. 
Non-steroidal anti-inflammatory drugs (NSAIDs), which decrease the formation of PGF2 alpha, 
are effective in alleviating dysmenorrhea. 5, 23 Indeed, NSAIDs are the most common 
pharmacologic treatment for dysmenorrhea. 19 The various formulations of NSAIDs have 
comparable efficacy for dysmenorrhoea, and pain relief is successfully achieved in between 64-
100% of women. 29, 34  Although the analgesic efficacy of NSAIDs has been well documented, no 
study has investigated whether attenuation of dysmenorrhea is associated with restoration of 
exercise performance, if that performance indeed is compromised by dysmenorrhea.  
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The aim of our study was two-fold. First, we aimed to assess whether moderate-to-severe 
dysmenorrhea decreases the exercise performance of healthy women in laboratory exercise 
performance tests, and, if so, to quantify the decrease in exercise performance. Secondly, we 
aimed to determine whether diclofenac potassium, which attenuates dysmenorrhea 8, 29, would 
restore any decreases in the women’s exercise performance to levels measured when the women 
were in the late-follicular pain-free phase of the menstrual cycle.  
 
METHODS 
Subjects 
Subject recruitment 
Healthy, null-partum university students were interviewed to assess their eligibility to participate 
in the study. Using a questionnaire, we obtained information regarding menstrual histories (age 
of onset of menses, length of cycle, age of onset of primary dysmenorrhea, timing and duration of 
pain, associated symptoms, severity of the pain, debilitation experienced, and any treatment 
interventions which successfully alleviated the pain). From the women’s menstrual cycle history 
and onset and duration of menstrual pain, we were able to identify women who fulfilled 
Dawood’s criteria for primary dysmenorrhea 13, and exclude women whose symptoms of pain 
were more indicative of secondary dysmenorrhea. In order for their menstrual pain to be 
classified as primary dysmenorrhea, the women’s menstrual pain needed to begin within two 
years of menarche, and occur just before menstruation or during menstruation. Recent onset of 
pain, or pelvic pain occurring at other times of the menstrual cycle, for example, in the luteal 
phase, is more indicative of secondary dysmenorrhea, and is related to pelvic abnormalities such 
as endometriosis and uterine malformations. 9, 13, 18, 19  
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Based on the above criteria, twelve women with a history of primary dysmenorrhea, who had 
experienced moderate-to-severe menstrual pain in the last 12 months, participated in the study. 
The women completed a general health questionnaire which screened them for chronic illnesses, 
joint and muscular abnormalities, and use of chronic medication. All of the women were healthy, 
and none of the women had taken chronic medication or hormonal therapy (oral contraceptives) 
in the 12 months before the study. None of the women were participating in structured exercise 
programs and described walking as their main source of physical exercise.  Ethical clearance was 
obtained from the University of the Witwatersrand’s Committee for Research on Human Subjects 
which adheres to the principles of the Declaration of Helsinki (protocol number M050310); all 
subjects gave written consent for participation. 
Procedures 
Study design 
The women completed an exercise-testing session in an exercise laboratory (Johannesburg, South 
Africa, 1753m above sea level), on three separate occasions, in the late afternoon (between 16:00 
and 17:00). One exercise-testing session took place during the late-follicular phase of the 
menstrual cycle (day 8-12), when the women were not menstruating and therefore not 
experiencing menstrual pain. The other two sessions took place on the first or second day of 
menstruation, when the women were experiencing their worst menstrual pain, and were taking 
either diclofenac potassium or placebo (see below). The sequence of the three exercise-testing 
sessions was randomized. The data was collected over three menstrual cycles, and the women 
were instructed to not exercise for three-to-four days before each test and to eat the same meal in 
the evening before the exercise session, and at 12:00 on the day of exercise testing. Furthermore, 
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the women were asked to maintain the same type of activity or exercise program during the three 
months of data collection (frequency, intensity and duration of exercise), and not to begin any 
new exercise programs.  
 
Drug administration 
For the two exercise sessions conducted when they were experiencing menstrual pain,  the 
women received, in a double-blind and crossover fashion, either diclofenac potassium (Cataflam 
D , Novartis, South Africa, 50mg per mouth), or an identical capsule of placebo (cane sugar, 
per mouth), between 07:00 and 08:00, and again at 13:00, on the day of testing. The diclofenac 
potassium and placebo were disguised in identical opaque gelatine capsules. The women were 
encouraged not to take rescue medication on the day of exercise testing, but, if needed, were 
allowed to take their usual anti nociceptive medication before 13:00, and were asked to record 
this medication. For the session performed in the late-follicular pain-free phase (day 8-12), the 
women received diclofenac potassium (50mg per mouth) in the morning at 07:00 and again at 
13:00 on the day of testing. The women were given diclofenac potassium to control for any 
ambiguous effects that diclofenac potassium may have on exercise independent of its pain-
relieving effects during menstruation.  
 
Measurement of pain 
The women were asked to quantify their dysmenorrhea using a visual analog scale (VAS), a 
100mm line anchored at “no pain” and “worst pain I have ever felt”. We chose the VAS because 
it has been shown to be an accurate assessment of intensity of menstrual pain in women with 
primary dysmenorrhea.8 The women completed the VAS in the morning of each testing day, 
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before taking the prescribed capsule, and then again just before beginning the exercise-testing 
session. They also completed the VAS during the rest periods between each exercise test.  
 
Exercise-testing protocol 
We conducted exercise tests to evaluate the leg strength, aerobic capacity and functional ability 
of the women. To warm up before beginning the exercise tests, the women walked for five 
minutes on a motorized treadmill (Powerjog E10, Birmingham, England) at 4km.h-1 and 0% 
gradient. The tests were conducted in the order described below, and the women rested for 15 
minutes between each test. The exercise testing, including the warm up, lasted between 60 and 80 
minutes. The exercise tests were conducted by the same investigator who was blinded to the 
women’s phase of the menstrual cycle and type of medication (placebo or diclofenac potassium). 
At each exercise session, the women were not told their performance times or results.  
 
Functional ability (task-specific test)  
We predicted that pain in the pelvic region would impair movement around the pelvis, but were 
unaware of any standard test that targets this region of the body. Therefore, we designed a task-
specific test that would assess the functional ability of the women to bend down and reach up 
(Figure 1). The women were encouraged to complete the task as quickly as possible, and their 
time to do so was recorded.  
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Figure 1 Schematic representation of the task-specific test. The test required the women to flex at 
the waist, lift up 1kg weights, and carry each weight for 3.5 meters from the ground to a ledge 
positioned 120mm above their heads. They carried eight of the 1kg weights, one at a time. Once 
all eight of the weights were on the raised ledge, the women carried each weight back to the 
ground position. The women were encouraged to complete the task as quickly as possible, and 
their time to do so was recorded.   
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Leg strength (1-RM test)    
A 45° incline leg-press machine (Cardio Genesis Fitness Systems, South Africa) was used to 
determine each woman’s one repetition maximum (1-RM) leg-press strength, that is, the 
maximum weight that she was able to lift once by extending her legs. Each woman attempted 
initially to lift 2.5 times her body mass. Depending on the outcome of her effort, the weight either 
was increased or decreased for subsequent attempts. Each woman was given four attempts to 
reach her 1-RM.  
 
Aerobic capacity (treadmill walking test) 
A modified version of the Bruce Protocol 30 was used to assess the aerobic capacity of each 
woman. We modified the original Bruce protocol to make the test more manageable for my 
subjects. The protocol assessed the women’s ability to walk up a steep incline on a motorized 
treadmill (Powerjog E10, Birmingham, England). For the first three minutes of the test, the 
women walked at a speed of 2.7km.h-1 on a 3% gradient, and then at 4km.h-1 (12% gradient) for 
the next three minutes. The women walked at 5km.h-1 for the remainder of the test, but the 
gradient was increased by 1% every three minutes until they were unable to continue. At the end 
of every minute, and at the end of the test, we recorded heart rate (Polar S610 Heart Rate 
Monitor, Polar Electro Oy, Kempele, Finland) and rating of perceived exertion (RPE) using the 
10-point Borg scale. 6 The control panel of the treadmill was not visible to the women during the 
test.    
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Data analysis 
The data, except for the RPE (median, upper and lower 95% CI), are expressed as mean ± SD. 
The VAS data was normalized with an arcsine transformation before parametric statistical 
analysis. The amount of weight (kg) lifted by the woman in the 1-RM test was divided by her 
body mass and expressed as a multiple of her body mass. For all statistical analyses P<0.05 was 
considered significantly different. 
 
 A two-way ANOVA, with time and agent administered as the main effects, was used to 
determine if there were differences in pain intensity after administration of diclofenac potassium 
and placebo in the morning of the exercise test, immediately before the exercise test, after the 
task-specific test, and at the end of the treadmill test. A Tukey post-test was used to detect 
differences when the ANOVA detected significant main effects or interactions.   
 
A repeated-measures ANOVA, with a Tukey post-test, was used to determine for performance 
differences in the three exercise tests and differences in the heart rate at the end of the treadmill 
test when the women were experiencing menstrual pain and taking either diclofenac potassium or 
placebo, and when they were not experiencing menstrual pain. Similarly, a Friedman test, with a 
Dunn post-test, was used to determine for differences in the RPE.  
 
RESULTS 
Subject characteristics and menstrual histories 
The physical characteristics and menstrual cycle histories of the twelve women are shown in 
Table 1.     
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   TABLE 1.  Subject characteristics and details of menstrual cycle history 
 
 
    Data shown as mean ± SD (n=12), * recorded over 3 menstrual cycles   
 
Five of the women routinely attempted to manage their menstrual pain using mild combination 
analgesics, which they considered to be unsuccessful in treating the pain. Two of the women 
were self-medicating occasionally with a non-steroidal anti-inflammatory drug (NSAID), and 
reported adequate pain relief when the NSAID was taken. The remaining five women were not 
taking medication. Except for those who were self-medicating with the NSAID, the women were 
dissatisfied with their current management strategies for their dysmenorrhea, and had accepted 
their menstrual pain as a normal, and intractable, female experience.  
 
Dysmenorrhea  
The women did not experience measurable pain on the late-follicular day of testing, before or 
after the exercise tests. In contrast, the women experienced moderate-to-severe pain during 
menstruation, before drug administration. Figure 2 shows the intensity of the women’s 
dysmenorrhea, as measured by the VAS, on the days of exercise testing during menstruation. 
                                                                     Women with dysmenorrhea 
Age (years)                                                             19.6 ± 1.7 
Body mass (kg)                                                      59.4 ± 9.5 
Height (m)                                                              1.62 ± 0.06 
Body mass index (kg.m2)                                       22.6 ± 3.4 
Age at onset of menses (years)                               12.8 ± 1.8 
Age at onset of dysmenorrhoea (years)                  13.7 ± 2.2 
Length of menstrual cycle (days) *                           27 ± 4 
Length of menstrual phase (days)*                             5 ± 2   
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Menstrual pain, measured in the morning, before drug administration, did not differ significantly 
between the two cycles (P>0.05). When the women received placebo, there was no alleviation of 
the pain; the pain measured before drug administration, before exercise, after the task-specific 
test, and after the treadmill test did not differ (P>0.05). Administration of diclofenac potassium, 
however, led to reduced pain ratings. The VAS scores before exercise, after the task-specific test, 
and after the treadmill test were not significantly different to each other (P>0.05), but were 
significantly lower than those before drug administration  (P<0.001), and those recorded at the 
same stages during exercise tests after placebo administration (P<0.001). 
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Figure 2 The intensity of dysmenorrhea, as measured by visual analog scale (VAS, back-transformed 
data, mean ± SD), of the women (n=12) on the day of the exercise-testing session. The VAS was 
completed in the early morning (07:00 to 08:00) before administration, double blind, of either 50 mg of 
diclofenac potassium (solid squares) or placebo (open squares). At 13:00, the women received another 
50mg of diclofenac potassium or placebo, and the VAS was completed again in the late afternoon (~ 
17:00) before they started the exercise-testing session, after the task-specific test, and after the treadmill 
test. * * * P< 0.001 compared to early morning VAS, # # # P< 0.001 compared to diclofenac potassium at 
same time. 
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Adverse reactions and need for rescue medication 
No woman reported any adverse reactions or side-effects during or after taking diclofenac 
potassium. None of the women took rescue medication during the day for any of the three 
exercise sessions.  
 
Exercise tests 
Figure 3 shows how long the women were able to exercise on the treadmill (panel A), and their 
heart rate (panel B) and RPE (panel C) recorded at the end of the treadmill test. There was a 
significant difference in the time spent on the treadmill (F=9.67, P=0.001), and in the heart rate 
(F= 17.48; P<0.0001) and RPE (P= 0.0004) responses at the end of the test. When the women 
were experiencing menstrual pain and taking placebo, compared to when they were in the late-
follicular pain-free phase of the menstrual cycle, they exercised for less time on the treadmill 
(P<0.05), and had a lower heart rate (P<0.001) and RPE (P<0.01) at the end of the test. However, 
administration of diclofenac potassium restored their exercise time on the treadmill, and returned 
their heart rate and RPE, measured at the end of the test, to values that were not statistically 
different to those recorded when they were in the late-follicular pain-free phase of the menstrual 
cycle (P>0.05).  
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Figure 3 The duration of the exercise which the women were able to do on the treadmill (min, mean ± SD, A), and 
the heart rate (beats/min, mean ± SD, B) and RPE (median, upper and lower 95% CI and range, C) of the women 
(n=12) when they elected to stop exercising on the treadmill, on the late-follicular day of the menstrual cycle (no 
menstruation, no pain), and when experiencing menstrual pain (menstruation) and taking either placebo or diclofenac 
potassium. * P<0.05 compared to diclofenac potassium, # P<0.05 compared to late-follicular day, ** P<0.01 
compared to diclofenac potassium, # # P<0.01 compared to late-follicular day, * * * P<0.001 compared to diclofenac 
potassium, # # # P<0.001 compared to late-follicular day. 
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Figure 4 shows the results of the task-specific test (panel A) and 1-RM test (panel B). There was 
a significant difference in performance on both tests when the women were experiencing 
menstrual pain and taking either placebo or diclofenac potassium, and when they were in the late-
follicular pain-free phase of the menstrual cycle (F=8.71, P=0.0016 for task-specific test; F=6.72, 
P=0.0053 for 1-RM test). When the women were experiencing menstrual pain and taking 
placebo, compared to when they were in the late-follicular pain-free phase of the menstrual cycle, 
their performance in the task-specific test was poorer (P<0.05), and they were less willing to 
exert effort in the 1-RM test (P<0.05). However, administration of diclofenac potassium restored 
their performance in the task-specific test and 1-RM to values that were not statistically different 
to those recorded when they were in the late-follicular pain-free phase of the menstrual cycle 
(P>0.05).  
  
                                                  
 
 
 
 
 
 
 85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 The time taken to complete the task-specific test (s, mean ± SD, A) and the weight lifted in the 
1-RM test (multiple of body mass, mean ± SD, B) in the women (n=12) on the late-follicular day of the 
menstrual cycle (no menstruation, no pain), and when experiencing menstrual pain (menstruation) and 
taking either placebo or diclofenac potassium.  
* P<0.05 compared to diclofenac potassium, # # P<0.01 compared to late-follicular day.  
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DISCUSSION 
We have shown that dysmenorrhea, but not the act of menstruation when the pain is relieved, 
decreases the performance of women in laboratory exercise tests. We predicted that 
dysmenorrhea, which is associated with pelvic pain, would decrease the women’s ability to 
perform a task requiring movement of the pelvic area. Indeed, compared to when the women 
were in the late-follicular phase of the menstrual cycle, and not experiencing menstrual pain, their 
ability to perform a test which required them to bend over and stretch upwards was decreased 
(Figure 1). We also found that the women performed poorly on standard exercise tests that 
required the use of their lower limb muscles. The women elected to walk for about 25% less time 
on the treadmill and stopped the exercise at a lower heart rate and rating of perceived exertion 
(RPE) compared to when they were in the late-follicular pain-free phase of the menstrual cycle. 
They were less willing to exert effort in the lower limb muscular strength test when they were 
experiencing menstrual pain.  However, administration of diclofenac potassium, taken as two 50 
mg doses six hours apart, was able to alleviate dysmenorrhea, and restore exercise performance 
to levels measured when the women were in the late-follicular pain-free phase of the menstrual 
cycle. Our study is the first to show the ability of a NSAID, taken during a time of dysmenorrhea, 
to restore the dysmenorrhea-related decrease in exercise performance to levels measured during 
the late-follicular pain-free phase of the menstrual cycle. 
 
Women have subjectively reported that moderate-to-severe dysmenorrhea decreases their 
participation in sports. 1, 20, 27, 35, 36  In questionnaire and retrospective surveys, women listed 
menstrual symptoms such as dysmenorrhea, fatigue, fluid retention and weight gain as limiting 
factors on sports activity and performance. 3, 4, 27 In the competitive sporting arena, swim 
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performance times were found to be significantly poorer at the beginning of menstruation when 
85% of the swimmers complained of fatigue, backache and lower abdominal pain, compared to 
the late-follicular phase when the swimmers were not menstruating. 4 Many studies have 
investigated the effect of menstrual cycle phase (follicular phase versus luteal phase) on exercise 
performance in laboratory-based protocols. 24, 27 In the studies that did find differences in athletic 
performance across the menstrual cycle, some measures of athletic performance were found to be 
decreased in the luteal phase, compared to the follicular phase. 24, 27 However, although some of 
these studies investigated measures of exercise performance in the early follicular phase (e.g., 
day 3 to day 8 of the menstrual cycle), the women were not experiencing moderate-to-severe 
menstrual pain. There have been no studies, to our knowledge, that have investigated whether 
exercise performance, measured objectively using standard exercise tests in a laboratory setting, 
is decreased in women experiencing moderate-to-severe menstrual pain compared to the late-
follicular phase when the women are not menstruating. Our study is the first to quantify the 
decrease in lower limb muscle strength and functional capacity of women when they are 
experiencing moderate-to-severe menstrual pain. When experiencing moderate-to-severe 
dysmenorrhea, and taking placebo, the women’s performance on the task-specific test decreased 
by almost 15%, and their willingness to exert effort in the lower limb leg strength test decreased 
by 20% compared to the late-follicular pain-free phase of the menstrual cycle. We specifically 
designed the task-specific test to target the pelvic region of the women with dysmenorrhea. The 
women’s decreased performance in the task-specific test, when given placebo, highlights the 
detrimental impact that moderate-to severe pelvic pain can have on a functional activity such as 
flexing at the waist and reaching upwards. Furthermore, the observation that the women chose to 
walk for 25% less time on the treadmill and stopped walking at a lower heart rate and RPE, 
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compared to when they were in the late-follicular pain-free phase of the menstrual cycle, implies 
that it was the pain, and not cardiovascular fatigue, that limited their exercise performance. 
Although we did not assess performance in a sporting event, or in an occupational setting, we 
predict that moderate-to-severe menstrual pain will impact negatively on sports or activities that 
require lower limb strength, aerobic capacity and repeated flexion and extension of the lumbar 
area. The decrease in exercise performance did not occur when the women’s menstrual pain was 
treated with diclofenac potassium. Unfortunately we did not measure other consequences of 
menstruation, other than pain, such as fatigue and fluid retention, which could impact negatively 
on exercise performance. We therefore cannot exclude that fatigue and fluid retention, and not 
only pain, may decrease exercise performance. However, we have shown that effective treatment 
of menstrual pain, using diclofenac potassium, was associated with decreased exercise 
performance.  
 
The women in our study suffered from moderate-to-severe menstrual pain which was confirmed 
by their VAS scores 10 and history of symptoms. 13 We recruited twelve women who successfully 
fulfilled all the criteria for participation in the study, and who were prepared to complete the three 
exercise sessions in the exercise laboratory. In spite of the relatively small sample size, we were 
able to show that diclofenac potassium not only had efficacy superior to placebo, but was also 
able to restore exercise performance to a level not different to that achieved in late-follicular 
pain-free phase of the menstrual cycle. Given that conclusion, it could have been considered 
unethical to have increased the sample size further and particularly to have required more 
subjects to take placebo.  
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Moderate-to-severe dysmenorrhea, if untreated, can be debilitating. 7, 12, 32, 35  The dysmenorrhea 
experienced by the women in our study, when treated with placebo, was similar in intensity to the 
pain reported by other patients with arthritis and dental pain, and can be described as moderate-
to-severe. 10  Diclofenac potassium, a NSAID which is able to decrease the formation of 
prostanoids, including PGF2 alpha, and to decrease uterine ischemia, was effective in alleviating 
menstrual pain before the late-afternoon exercise-testing session. The efficacy of diclofenac and 
other NSAIDs such as ibuprofen, naproxen, rofecoxib and valdecoxib, in alleviating menstrual 
pain, has been documented. 8, 11, 14, 29  In our study, administration of just 100mg diclofenac 
potassium, as 50mg in the early morning on the day of the exercise-testing session, and 50mg 
again at midday, not only attenuated the menstrual pain, but restored the exercise performance to 
levels measured when the women were in the late-follicular pain-free phase of the menstrual 
cycle.  
 
In our study, the exercise session did not result in an endogenous-mediated analgesic effect, as 
seen in other studies. 21, 22  However, there is some evidence that exercise intensities of over 70% 
of maximal aerobic capacity are required to cause analgesia, and that pain threshold increases 
with increasing intensities above this level. 26 In our study, it may well be that the exercise 
intensity was not sufficient to cause analgesia. However, what we did show was that the exercise 
session did not increase the women’s pain; there was no significant difference in the women’s 
intensity of menstrual pain, when taking placebo, before the exercise session, compared to after 
the exercise session.    
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Our study has shown that diclofenac potassium, by relieving moderate-to-severe dysmenorrhea, 
restores the pain-related decrease in exercise performance. Primary dysmenorrhea in women of 
child-bearing age is common, and the pain is poorly-managed and debilitating. 2, 25  We have 
shown that a single intervention, giving the recommended daily dose of a readily-available 
NSAID, diclofenac potassium, is effective in relieving menstrual pain, and restoring physical 
performance to levels achieved when the women were in the late-follicular pain-free phase of the 
menstrual cycle. Future studies should attempt to quantify the effect of moderate-to-severe 
dysmenorrhea on competitive sports performance. If that performance indeed is compromised, 
diclofenac potassium, an unbanned drug, could be effective in restoring sporting performance. 
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 ABSTRACT 
We assessed whether an activity data logger was able to detect, and measure, the reduced 
physical activity reported by women with moderate-to-severe primary dysmenorrhea. Twelve 
young women with a history of primary dysmenorrhea, and twelve young women without a 
history of dysmenorrhea, wore an activity data logger on their hip for three days when 
menstruating, and for three matched days of the week when not menstruating.  A visual analog 
scale was use to assess intensity of pain. When menstruating, the women with a history of 
primary dysmenorrhea, compared to when they were not  menstruating, were significantly less 
active, by about 40%, on their day of worst pain (P=0.00016), day of intermediate pain 
(P=0.00019) and day of least pain (P=0.00019). There was no significant difference in the 
voluntary physical activity of the group on the three menstrual days. The women without a 
history of dysmenorrhea experienced mild menstrual pain, but no significant decrease in physical 
activity (P=0.82). We show that data loggers are able to detect and quantify the decrease in 
physical activity reported by the women with a history of moderate-to-severe dysmenorrhea, and 
that menstrual pain, but not menstruation itself, was associated with decreased voluntary physical 
activity. 
 
Perspective 
 
We have shown that a miniature activity data logger, worn on the hip, was able to detect, and 
quantify, the decrease in physical activity reported by women with moderate-to-severe primary 
dysmenorrhea. The women’s 24-hour physical activity was depressed to about two-thirds of the 
activity measured when they were not menstruating. Actigraphy is a useful tool for measuring 
pain-related debilitation and its management.  
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INTRODUCTION 
The cramping pain which women of child-bearing age experience in the lower abdomen just 
before menstruation or during menstruation, in the absence of any pelvic pathology, is called 
primary dysmenorrhea.9 The pain is most severe during the first or second day of menstruation, 
and causes “extensive personal and public health problems, a high degree of absenteeism, and 
severe economic loss.9 “ Like patients who have painful conditions such as fibromyalgia, lower 
back pain and osteo-arthritis, 12, 17, 20, 22, 30, 32 women with dysmenorrhea report decreased physical 
and functional activity.14 Physical activity questionnaires and activity recall diaries are the most 
widely-used methods for the assessment of physical activity in patients.1, 5, 36, 37 Questionnaires 
and recall diaries are subjective and their accuracy relies on subject compliance and subject 
fluency in the language of the questionnaire. As a result, they are only suitable for certain 
population groups and can be inaccurate if completed incorrectly. 8, 33  In order to eliminate many 
problems associated with self-report measures, it is necessary to explore alternative methods that 
do not rely on the individuals’ ability to recall activity, or on the quality of the questionnaire.13   
 
An alternative to the questionnaires and diaries, not requiring the same degree of compliance, and 
generating objective measurement of activity, is the assessment of activity, via activity data 
loggers.29, 39 Typically, activity data loggers are small, unobtrusive devices, worn on the hip, wrist 
or ankle, which can measure activity minute-by-minute, with little intervention by the observer, 
over days, weeks or months. Because activity data loggers provide an objective and quantifiable 
measure of physical activity, without hindering movement, they have become popular for 
measuring physical activity in both healthy people and patients. 4, 20, 25, 31, 34  In patients 
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experiencing pain, actigraphy is emerging as a useful tool to measure the debilitating effects of 
the pain, 20, 25 or to detect the effects of physical, surgical or pharmacological interventions.     
 
The main aim of our study was to assess whether a miniature activity data logger, attached at the 
hip, was able to detect, and measure quantitatively, the reduced physical activity reported by a 
group of women with a history of moderate-to-severe primary dysmenorrhea. To control for the 
possibility that menstruation, and not pain, could decrease physical activity levels, a group of 
women without a history of primary dysmenorrhea, who described their menstrual pain as not 
activity-limiting, wore the data logger for three days of menstruation, and then again for three 
days when they were not menstruating.  
 
METHODS 
Subject recruitment 
Healthy, null-partum university-residence students were interviewed to assess their eligibility to 
participate in the study. Using a questionnaire, we obtained information regarding menstrual 
histories (age of onset of menses, length of cycle, age of onset of primary dysmenorrhea, timing 
and duration of pain, associated symptoms, severity of the pain, debilitation experienced, and any 
treatment interventions which successfully alleviated the pain). From the women’s menstrual 
cycle history and onset and duration of menstrual pain, we were able to identify women who 
fulfilled Dawood’s criteria for primary dysmenorrhea, 10 and exclude women whose symptoms of 
pain were more indicative of secondary dysmenorrhea. In order for their menstrual pain to be 
classified as primary dysmenorrhea, the women’s menstrual pain needed to have begun within 
two years after menarche, and occur just before menstruation or during menstruation. 10, 14 Recent 
 101 
onset of pain, or pelvic pain occurring at other times of the menstrual cycle, for example, in the 
luteal phase, is more indicative of secondary dysmenorrhea, and is related to pelvic abnormalities 
such as endometriosis and uterine malformations. 10, 14 Women with a history of menstrual 
symptoms more indicative of secondary dysmenorrhea were not included in the study. In 
addition, each woman completed an activity questionnaire which elicited information about the 
frequency, intensity, nature and duration of any physical activity in which she participated. Using 
the questionnaire data, we identified a cohort of 24 women who did not participate in structured 
exercise programs or sporting events, and described walking as their main form of exercise. From 
these 24 women, we identified 12 women with a history of primary dysmenorrhea and 12 women 
without such a history. The women with a history of dysmenorrhea all had experienced moderate-
to-severe menstrual pain in the last 12 months. The women without a history of dysmenorrhea 
had experienced no menstrual pain, or slight pain, in the last year. The two groups of women 
were not informed about the aims of the study.  
Procedures 
Measurement of voluntary physical activity level 
The women wore a physical activity data logger, the Actical ® (Mini-Mitter Co, Oregon, USA), 
for six days of their menstrual cycle.  The Actical ® activity logger uses an omni-directional 
accelerometer to monitor the occurrence and intensity of motion. The activity data logger was 
attached to an elastic belt and mounted over the right iliac crest of each woman. The logger was 
orientated to be most sensitive to movements in the vertical plane, as would occur with walking 
and running. The activity data logger had dimensions of 28 x 27 x 10mm, and weighed 17grams, 
and was capable of recording physical activity without hindering movement.16 Women from both 
groups wore the activity data logger for three consecutive days starting on the first day of 
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menstruation, and, later, for another three consecutive days during the follicular phase of their 
menstrual cycle, starting on the same day of the week as had the first day of menstruation. We 
did not record physical activity at times when the women were likely to have unusually reduced 
or increased physical activity, for example, when studying for examinations or on vacation. The 
women wore the activity data logger for 24 hours per day, except when showering or bathing. 
Each woman wore the same activity data logger for all six measurement days. The women were 
unable to view or access any of the data on the data logger. The activity data logger was 
programmed to record the mean hourly activity, which we downloaded after the three days 
(Actical ® software version 2.0, Mini-Mitter Co, Oregon, USA). 
 
Subjective measurement of impact of pain on physical activity 
On each of the menstrual days, the women were asked to complete a simple physical activity 
questionnaire. The women were asked to indicate on the questionnaire whether their physical 
activity was unaffected, rarely affected, moderately affected or severely affected by menstrual 
pain. In addition, the women were asked to record the time when they went to bed in the evening.    
 
Measurement of pain and use of anti-nociceptive medication 
Women with a history of dysmenorrhea, and those without, were asked to quantify their pain 
using a visual analogue scale (VAS), a 100mm line anchored at “no pain” and “worst pain I have 
ever felt”. The women completed the VAS in the morning and in the evening on each of the three 
menstrual days and on each of the three non-menstrual days. Ethically, the women were allowed 
to take their usual anti-nociceptive medication for their menstrual pain, but we asked them to try 
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and delay the use of medication until absolutely necessary. The women recorded the name and 
dose of any anti-nociceptive medication which they took during the study.   
   
Data analysis 
The data are expressed as mean ± SD. The VAS data were normalised with an arcsine 
transformation before parametric statistical analysis. P<0.05 was considered significantly 
different.  
 
Intensity of pain and physical activity counts in both groups of women  
Each woman’s morning and evening VAS scores were used to calculate a mean VAS for each 
day when menstruating and when not menstruating. The mean daily VAS scores were used to 
rank their three menstrual days into the day of worst pain (highest VAS score), day of 
intermediate pain (intermediate VAS score), and day of least pain (lowest VAS score).  
 
To account for variability between activity data loggers, and for inter-individual variability in 
habitual physical activity, each woman’s mean  hourly activity count for the two three-day 
sessions was expressed as a percentage of the highest count recorded for that specific activity 
data logger when worn by that woman. Mean activity was calculated for each woman over the 
three follicular days (mean follicular day). During menstruation, physical activity was calculated 
for the day of worst menstrual pain, the day of intermediate menstrual pain, and the day of least 
menstrual pain. A two-way ANOVA, with pain intensity and group as the main effects, was used 
to determine for differences in pain intensity and physical activity on the mean follicular day, day 
of worst menstrual pain, day of intermediate menstrual pain, and day of least menstrual pain, in 
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the two groups of women. A Student-Newman-Keuls’s (SNK) post-test was used to detect for 
differences within and between groups when the ANOVA detected significant main effects or 
interactions.   
    
To analyse whether any changes in physical activity occurred during sleep or wakefulness, the 
mean physical activity for the day of worst menstrual pain and the mean physical activity for the 
three follicular days were separated into times when the women were awake and when they were 
in bed. A two-way ANOVA, with pain intensity and group as the main effects, was used to 
determine for differences in awake physical activity, and in bed physical activity, on the mean 
follicular day and day of worst menstrual pain, in the two groups of women. A Student-Newman-
Keuls’s (SNK) post-test was used to detect for differences within and between groups when the 
ANOVA detected significant main effects or interactions. 
   
In the women with a history of dysmenorrhea, and those without, a Pearson’s product-moment 
linear correlation was used to investigate the relationship between the mean daily pain intensity 
and mean daily physical activity, over the three days of menstruation.  
 
Subjective measurement of impact of pain on physical activity 
Fisher’s exact tests were used to test whether the physical activity of the women with a history of 
dysmenorrhea, compared to the women without such a history, was more likely to be moderately-
to-severely affected on the day of worst menstrual pain, day of intermediate menstrual pain, and 
day of least menstrual pain.  
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Similarly, Fisher’s exact tests were used to determine whether the women with a history of 
dysmenorrhea were more likely to perceive their physical activity to be moderately-to-severely 
affected by menstrual pain on the day of least pain, day of intermediate pain, and day of worst 
pain (Bonferroni correction for multiple comparisons).       
 
Ethical clearance 
Ethical clearance was obtained from the University of the Witwatersrand’s Committee for 
Research on Human Subjects (protocol number M040534); all subjects gave written informed 
consent for participation. 
 
RESULTS 
Subject characteristics and menstrual histories 
 
The physical characteristics and menstrual cycle histories of the two groups of women are shown 
in Table 1. Ethnically, there were no differences between the two groups of women. None of the 
women were participating in structured exercise programs or sporting events; they all listed 
walking as their main type of exercise. None of the women were taking oral contraceptives. Five 
of the women with a history of dysmenorrhea were attempting to manage their menstrual pain 
using mild over-the-counter combination analgesics, which they considered to be unsuccessful in 
treating the pain.  Another woman, who used a non-steroidal anti-inflammatory drug, reported 
marginal pain relief. The remaining six women were not taking medication for menstrual pain. 
None of the women with dysmenorrhea were seeking better relief of their pain.  
 
 
 106 
TABLE 1. Subject characteristics and details of menstrual cycle history 
 
 
 
 
 
 
 
 
 
Data shown as mean ± SD   * recorded over time of data collection 
 
 
 
None of the women without a history of dysmenorrhea was using anti-nociceptive medication 
during menstruation.  
 
Intensity of dysmenorrhea and use of anti-nociceptive medication 
Figure 1 shows the intensity of the dysmenorrhea, as measured by the VAS, when the women 
with a history of dysmenorrhea (panel A) and the women without a history of dysmenorrhea 
(panel B) were not menstruating (i.e., on follicular days), and on three menstrual days, ranked 
according to pain intensity on the day. As expected, when the women were not menstruating, 
they did not report any pain. In eighteen of the women, the first day of menstruation was their 
most painful day, and in six it was the second day. There was a significant group effect (P<0.001, 
F1,22 =54.55), pain intensity effect (P<0.001, F3,66 = 105.37), and a significant interaction effect 
(P<0.001, F3,66  = 24.97) for the two groups of women (Figure 1).  
 
 
History of dysmenorrhea 
           Yes                               No 
Number of subjects        12            12 
Age  (years) 
       22 ± 3            23 ± 2 
Body mass (kg) 
       63 ± 4            64 ± 5 
Age of menarche (years) 
       12.3 ± 2.3            11.8 ± 3.2 
Age at onset of dysmenorrhea (years) 
       13.3 ± 2.6  
Duration of menstrual cycle (days) * 
       28 ± 3            30 ± 3 
Duration of menstrual phase (days) * 
       5 ± 2            4 ± 2 
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FIGURE 1. The intensity of dysmenorrhea, as measured by Visual Analog Scale (VAS, back transformed data, mean ± SD), of 
the women with a history of dysmenorrhea (panel A) and the women without a history of dysmenorrhea (panel B) when they were 
not menstruating (follicular days, mean of three days), and on their day of least menstrual pain, day of intermediate menstrual 
pain, and day of worst menstrual pain. When the women were not menstruating, they did not report any pain. 
* * * P<0.001 compared to menstrual days, + + + P<0.001 compared to day of intermediate and day of worst menstrual pain, # # 
# P<0.001 compared to day of worst menstrual pain, # P<0.05 compared to day of worst menstrual pain, $ P<0.05 compared to 
day of worst menstrual pain.   
 
In the women with a history of dysmenorrhea, compared to the corresponding menstrual days in the women without a history of 
dysmenorrhea, the intensity of menstrual pain was significantly worse on the day of least menstrual pain (P<0.01, SNK), day of 
intermediate menstrual pain (P<0.001, SNK), and day of worst menstrual pain (P<0.001, SNK). There was no difference in the 
intensity of menstrual pain in the women with a history of dysmenorrhea on their day of least menstrual pain compared to the 
intensity of pain in the women without a history on their day of worst menstrual pain.       
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In the women with a history of dysmenorrhea (Figure 1A), the intensity of their dysmenorrhea, 
measured during the study, depended significantly on their state of menstruation. The intensity of 
pain on their follicular day was significantly less than the intensity of pain on their day of least 
pain (P<0.001, SNK), day of intermediate pain (P<0.001, SNK), and day of worst pain (P<0.001, 
SNK). The intensity of their pain on their day of least menstrual pain was significantly less than 
the intensity of pain on their day of intermediate menstrual pain (P<0.001, SNK) and on their day 
of worst menstrual pain (P<0.001, SNK), and the intensity of their pain on their day of 
intermediate menstrual pain was significantly less than on their day of worst menstrual pain 
(P<0.001, SNK). Nine of the women with a history of dysmenorrhea did not take anti-nociceptive 
medication when experiencing menstrual pain during our study. One woman took a non-steroidal 
anti-inflammatory drug (ibuprofen, 1200mg per day) on the first day of menstruation, and two 
women took acetaminophen (500mg 2-3 times per day) on the first day of menstruation. On their 
day of worst menstrual pain the women rated their pain at 57 mm + 11 mm, -12 mm (mean + SD, 
-SD), on the VAS.  
 
Women in the group selected because they did not report a history of dysmenorrhea (Figure 1B) 
nevertheless reported menstrual pain during the study, the intensity of which depended 
significantly on their state of menstruation. Compared with follicular days, they reported worse 
menstrual pain on their day of least pain (P<0.001, SNK), day of intermediate menstrual pain 
(P<0.001, SNK), and day of worst menstrual pain (P<0.001, SNK). When the women were 
menstruating, the intensity of menstrual pain on their day of worst pain was significantly greater 
than the intensity of pain on their day of least menstrual pain (P<0.05, SNK), and on their day of 
intermediate menstrual pain (P<0.05, SNK). There was no significant difference between the 
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intensity of menstrual pain on their day of intermediate pain and their day of least pain. The 
women without a history of dysmenorrhea did not use anti-nociceptive medication during 
menstruation, and on their day of worst menstrual pain, reported the pain intensity as 10 mm + 8 
mm, -9 mm (mean + SD, -SD), on the VAS.  
 
The intensity of menstrual pain was significantly greater in the women with a history of 
dysmenorrhea, compared to the women without a history of dysmenorrhea, on the day of least 
menstrual pain (P<0.01, SNK), day of intermediate menstrual pain (P<0.001, SNK), and day of 
worst menstrual pain (P<0.001, SNK). In the women with a history of dysmenorrhea, the 
intensity of menstrual pain, on the day of least menstrual pain, was not significant different than 
the intensity of pain in the women without a history of dysmenorrhea on their day of worst 
menstrual pain.  
 
Physical activity 
Subjective measurement of impact of pain on physical activity 
Compared to the women without a history of dysmenorrhea, the physical activity of the women 
with a history of dysmenorrhea was more likely to be moderately and severely affected on the 
day of worst menstrual pain (P<0.001; Fisher’s exact test), day of intermediate menstrual pain 
(P<0.001; Fisher’s exact test), and day of least menstrual pain (P<0.05; Fisher’s exact test). 
 
In the women with a history of dysmenorrhea, there was no significant difference in the number 
of women who perceived that their physical activity was moderately-to-severely affected by 
menstrual pain on the day of worst menstrual pain compared to the day of intermediate menstrual 
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pain (P=0.22, Fisher’s exact test), and on the day of intermediate menstrual pain compared to the 
day of least menstrual pain (P=0.40; Fisher’s exact test). However, significantly more women 
perceived that their physical activity was moderately-to-severely affected by menstrual pain on 
their day of worst menstrual pain compared to their day of least menstrual pain (P=0.02, Fisher’s 
exact test).  
 
Objective assessment of physical activity 
The activity data loggers were removed only when the women bathed or showered. The women 
reported that the logger was simple to re-attach, and, when worn on the hip, did not interfere with 
their daily activities or influence their sleep. Figure 2 shows the physical activity, as measured by 
the activity data loggers, when the women with a history of dysmenorrhea (panel A) and the 
women without a history of dysmenorrhea (panel B) were not menstruating (i.e., on follicular 
days), and on three menstrual days, ranked according to pain intensity on the day. There was a 
significant group effect (P<0.001, F1,22 =32.03), a significant pain intensity effect (P<0.001, F 
3,66=10.49) and a significant interaction effect (P<0.001, F3,66  = 12.64) for the two groups of 
women (Figure 2). 
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FIGURE 2. The physical activity (percentage of maximum recorded activity for each woman, mean ± SD) of the women with a 
history of dysmenorrhea (panel A) and women without a history of dysmenorrhea (panel B) when not menstruating (follicular 
days, mean of three days), and on their day of least menstrual pain, day of intermediate menstrual pain and day of worst menstrual 
pain. * * * P<0.001 compared to menstrual days. 
 
There was no significant difference in physical activity between the two groups of women when they were not menstruating, but 
physical activity was significantly reduced in the women with a history of dysmenorrhea, compared to the women without a 
history of dysmenorrhea, on the three corresponding days of menstruation (P<0.001, SNK). In the women with a history of 
dysmenorrhea, the physical activity, on the day of least menstrual pain, was significant lower than the physical activity in the 
women without a history of dysmenorrhea on their day of worst menstrual pain (P<0.001, SNK).  
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In the women with a history of dysmenorrhea (Figure 2A), there was a significant reduction in 
the physical activity of the women when they were experiencing menstrual pain. When the 
women were not menstruating (follicular days), their physical activity was significantly higher 
than on the day of worst menstrual pain (P<0.001, SNK), day of intermediate menstrual pain 
(P<0.001, SNK) and day of least menstrual pain (P<0.001, SNK), but their physical activity did 
not differ significantly between the three days of menstrual pain. Mean activity over those three 
days was 58 ± 18% (mean ± SD) of the activity of the same women averaged over the three 
follicular days.  
  
In the women without a history of dysmenorrhea (Figure 2B), there was no significant difference 
in physical activity over the days of the menstrual cycle which we studied. The physical activity 
was significantly greater in the women with a history of dysmenorrhea, compared to the women 
without a history of dysmenorrhea, on the day of least menstrual pain (P<0.001, SNK), day of 
intermediate menstrual pain (P<0.001, SNK), and day of worst menstrual pain (P<0.001, SNK), 
but not on the follicular day.  In the women with a history of dysmenorrhea, the physical activity 
on the day of least menstrual pain was significantly lower than the physical activity in the women 
without a history of dysmenorrhea on their day of worst menstrual pain (P<0.001, SNK).  
 
In the women with dysmenorrhea, the reduction in physical activity during menstruation occurred 
entirely as a consequence of reduced daily activities while awake. Figure 3 shows their activity 
while awake or in bed, of the women with a history of dysmenorrhea (panel A), and the women 
without a history of dysmenorrhea (panel B), on their day of worst menstrual pain, and when they 
were not menstruating.  
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For the awake physical activity data, there was no significant group effect (P=0.13, F1,22 =2.57), 
and no significant interaction effect (P=0.27, F1, 22 = 1.28), but there was a pain intensity effect 
(P<0.01, F1,22 = 13.24). In the women with a history of dysmenorrhea, the awake physical activity 
was significantly greater on the follicular day compared to the day of worst pain (P<0.001, SNK). 
For the in bed physical activity data (Figure 3), there was no significant group effect (P=0.83, 
F1,22 = 0.046), and no significant pain intensity effect (P=0.32, F1,22 = 1.01), and no significant 
interaction effect (P=0.94, F1,22 = 0.0054) for the two groups of women.   
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FIGURE 3: The physical activity (percentage of maximum recorded activity for each woman, mean ± SD) of the 
women with a history of dysmenorrhea (panel A) and women without a history of dysmenorrhea (panel B) when not 
menstruating (follicular days, mean of three days), and on their day of worst menstrual pain, while they were awake 
(open bars) or in bed (closed bars). * * * P<0.001 compared to day of worst menstrual pain.  
 
There was no statistical difference between awake and in bed physical activity in the two groups of women when 
they were not menstruating, and when they were experiencing their day of worst menstrual pain.  
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Correlation between intensity of pain and physical activity count 
In the women with a history of dysmenorrhea, there was no significant correlation between the 
intensity of menstrual pain and the mean 24 hour physical activity on the day of least menstrual 
pain (r=0.48, P=0.12), day of intermediate menstrual pain (r= -0.52, P=0.06) and day of worst 
menstrual pain (r=-0.19, P=0.54). However, as seen in Figure 4,  there was a significant linear 
inverse correlation between the intensity of menstrual pain and  the mean awake physical activity 
on the day of worst menstrual pain (y=- 0.1989x + 24.37, r=-0.62, P=0.03). Using the regression 
equation, if the women rated their pain as 100mm on the VAS, or the worst pain ever 
experienced, then we estimate that activity would decrease to 5% of the maximum recorded 
activity. 
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FIGURE 4: Linear regression (with 95% confidence limits) between awake physical activity 
(percentage of maximum recorded activity for each woman) and intensity of pain (VAS) on the 
day of worst menstrual pain in the women with a history of dysmenorrhea (n=12). There was a 
significant inverse linear correlation between physical activity and pain intensity (y=- 0.1989x + 
24.37, r=-0.62, P=0.03). Using the regression equation, the predicted pain intensity at which all 
activity would cease, would have to be 120mm on the 100mm VAS. If the women rated their 
pain as 100mm on the VAS, then activity would drop to 5% of the maximum recorded activity. 
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DISCUSSION 
We have shown that activity data loggers are able to detect, and quantify, the decrease in 
everyday physical activity reported by the women with a history of moderate-to-severe 
dysmenorrhea. Physical activity, recorded every hour by an activity data logger, over three days 
of menstruation, was lower than that recorded when the women were in the follicular phase of 
their menstrual cycles, on days of the week matched to those of the three days of menstrual pain. 
Although the intensity of pain varied over the three days of menstruation, the 24-hour physical 
activity of the group of women was similar on these three menstrual days, and depressed to about 
two-thirds of the 24-hour activity on follicular days. Both pain intensity and depression of 
physical activity varied between the women in our cohort, and, on the day of the worst menstrual 
pain, the awake physical activity was correlated inversely and linearly with the pain intensity 
experienced by that woman. However, according to the co-efficient of determination from the 
regression, pain intensity accounted for less than half of the variability in physical activity 
between the women.  
 
The depression in physical activity did not occur in the women without a history of 
dysmenorrhea. Even though they too did experience slight pain during menstruation, the women 
who did not report a history of dysmenorrhea, and described their menstrual pain as not activity-
limiting, in the activity questionnaires, showed no significant change in physical activity when 
they were menstruating.  We have shown, therefore, that it was dysmenorrhea, and not other 
consequences of menstruation, that was associated with decreased physical activity. Although the 
menstrual cycle length of the two groups of women were similar (Table 1) we did not ask the 
women to comment on the heaviness of their menstrual flow, nor did ask the women to record the 
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usage of feminine products during menstruation. Therefore, we cannot exclude the possibility 
that increased menstrual flow in the women with dysmenorrhea may have decreased their 
physical activity. 
 
The activity which we have reported to be depressed in women with dysmenorrhea was measured 
over the full 24-hour day. However, we might have expected nocturnal activity to be increased in 
those women, if their pain resulted in restless sleep. Our data showed, however, that there was no 
change in nocturnal activity between the follicular and menstrual phases, in the women with 
dysmenorrhea, and nor was there any difference in nocturnal physical activity during 
menstruation between the women with and without a history of dysmenorrhea. Dysmenorrhea 
does alter sleep architecture 2, including increasing awakenings during sleep, but, in the women 
in our study, did not result in nocturnal activity, such as increased in-bed movement or even 
walking around, which would have been detected by our data loggers. However, actigraphy has 
been used to show an increase in night-time movement, indicating disrupted sleep, in women 
with fibromyalgia 21, 23 and in patients with migraine. 6 In our study, more-sensitive triaxial 
accelerometers, or accelerometers attached to the wrist, might detect increased restlessness in 
bed, associated with dysmenorrhea, in which case we would have underestimated the depression 
in physical activity over the full 24 hours. Triaxial accelerometers might also detect more-subtle 
changes in diurnal physical activity in women with dysmenorrhea. In our study, we used an 
omni-directional activity data logger which was attached at the waist and was positioned to be 
most sensitive to movement in the vertical plane, such as that generated by walking. So the 
physical activity that we have shown to be so markedly depressed was the activity of walking, or 
other gross body movement. Multiple accelerometers would allow detection of physical activity 
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such as arm movement without gross body movement. However, even they would not detect 
isometric muscle contraction. What activity loggers measure is body accelerations, and not 
metabolic rate. These accelerations were depressed in women going about their daily business, 
when they experienced dysmenorrhea.  
 
In epidemiological studies investigating the effect of dysmenorrhea on physical well-being, 
questionnaires and activity recall diaries, because of their ease of administration, relative 
inexpensiveness, and noninvasiveness, are commonly used to assess physical activity.15 We have 
shown that an activity data logger was able to detect the decrease in physical activity reported by 
the women with dysmenorrhea, and actigraphy potentially offers a useful tool to objectively 
quantify the debilitating effects of dysmenorrhea. However, we still need to assess whether the 
decrease in physical activity, as measured by the data logger, and the decrease in physical 
activity, as measured by a comprehensive and validated activity questionnaire, are similar.  
  
 Activity data loggers allow for an objective and quantifiable measure of physical activity. 
Subjects are likely to recall vigorous, structured activity with a high degree of accuracy, but are 
not as accurate when recalling frequent, moderate-intensity activities such as walking.3 Walking 
is the major contributor to physical activity in normal life. 24, 28, 35 Subjective reporting of 
physical activity performed may be influenced by the perceived desirability of a given response 
19
, as well as inaccurate perception of activity behaviour.13 Most of us overestimate our physical 
activity when allowed to assess the level of exertion of specific activities. In patients 
experiencing pain, actigraphy is emerging as a useful tool to measure the debilitating physical 
effects of the pain. 18, 20, 25 Actigraphy has been used to show a decrease in physical activity in 
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patients with tension-type headache 18, women with fibromyalgia 20, 21, and in adolescents with 
chronic pain. 25 In women with fibromyalgia, physical activity levels are recorded more 
accurately using ambulatory activity monitoring as compared with retrospective self-report. 21   
 
In our study, the women with a history of dysmenorrhea fulfilled Dawood’s criteria for the 
diagnosis of primary dysmenorrhea.10 The physical characteristics and menstrual histories of 
these women were not different from those of the women without a history of dysmenorrhea, and 
were similar to those of the subjects of other studies of dysmenorrhea.2, 40 According to research 
which has used the VAS to measure intensity of pain in conditions such as arthritis and dental 
pain 7, the pain intensity of the women in this study with a history of dysmenorrhea would be 
classified as “mild” on the day of least menstrual pain, “moderate” on the day of intermediate 
menstrual pain and “moderate-to-severe” on the day of worst menstrual pain. In comparison, 
even on their day of worst pain, the women without a history of dysmenorrhea experienced only 
“mild” pain during menstruation. Thus, when women reported to us that they had no history of 
dysmenorrhea, what they meant was that they had only mild pain, and not that they were free of 
pain during menstruation. In those women, menstrual bleeding, which often can be bothersome or 
annoying, did not suppress physical activity, measured objectively.  
 
In the women with a history of dysmenorrhea, the intensity of the pain varied over the days of 
menses. That allowed us to select days of worst menstrual pain (usually, but not always, the first 
day of menstruation), intermediate and least menstrual pain, between which the pain intensity 
varied significantly. Anomalously, though, physical activity was depressed equally on these days, 
even though, between women, activity was dependent on individual pain intensity. The anomaly 
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could have a statistical origin. There may have been a real change in activity, disguised by 
variability within the group, even though we used two-way ANOVA for the analyses. However, 
power analysis showed that we would require a cohort of 66 women to achieve a significant 
difference in activity on the day of worst and least menstrual pain. Alternatively, the anomaly 
could have a biological origin.  It is possible that the women with a history of dysmenorrhea 
associate their menstrual bleeding with recurrent pain that will range from mild to severe over the 
menstrual phase and therefore, either consciously or unconsciously, decrease their physical 
activity when menstruation begins. The practical implication of our results, though, is that one 
should expect any women with a history of moderate-to-severe dysmenorrhea to have reduced 
voluntary physical activity over three days of menstruation. 
 
The aim of our study was to determine whether a physical activity data logger, worn by women 
with a history of moderate-to-severe dysmenorrhea, was able to detect the decrease in physical 
activity reported by these women. Therefore, on each of the menstrual days, women with a 
history of dysmenorrhea, and women without such a history, were asked to complete a simple 
questionnaire investigating whether they thought their physical activity was unaffected, rarely 
affected, moderately affected or severely affected by menstrual pain. Compared to the women 
without a history of dysmenorrhea, women with such a history were more likely to report that 
their physical activity was moderately-to-severely affected by menstrual pain on their day of 
worst menstrual pain (all twelve women), day of intermediate menstrual pain (nine women) and 
day of least menstrual pain (six women). The physical activity data obtained from the data 
loggers was in agreement with the subjective opinion of the women; 24-hour physical activity 
was significantly reduced, in the women with a history of dysmenorrhea, compared to the women 
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without a history of dysmenorrhea, on their day of least menstrual pain (decreased by 41%), day 
of intermediate menstrual pain (decreased by 47%), and day of worst menstrual pain (decreased 
by 58%) (Figure 2). Therefore, actigraphy potentially offers a useful tool to detect the decrease in 
physical activity reported by the women with moderate-to-severe menstrual pain.  
 
Activity data loggers allow for an objective assessment of physical activity, and are particularly 
useful outside the laboratory or hospital setting, in free-living people. They are unobtrusive, do 
not impede movement, and are compatible with most daily activities.27, 38 Furthermore, activity 
data loggers are valid and reliable instruments for the measurement of dynamic physical 
activities, such as walking.11, 39 Though the inexpensive loggers we used served our purpose 
adequately, more-sensitive loggers based on triaxial accelerometers are available commercially. 
We believe that actigraphy potentially is a valuable tool with which to measure the extent to 
which dysmenorrhea, and other types of pain,  interfere with normal daily life, and to assess, in a 
community setting, the success of pain management. 
 
ACKNOWLEDGEMENTS 
Our research was funded by a Faculty Research Committee Individual Grant (University of 
Witwatersrand), and by the National Research Foundation, South Africa. We did not receive any 
funding or donations from Mini-Mitter Co. We thank our subjects for participating in the study.     
 
 
 
 
 
 
 
 123 
REFERENCES 
 
 
1 Aaron DJ, Kriska AM, Dearwater SR, Cauley JA, Metz KF, LaPorte RE: Reproducibility and 
Validity of an Epidemiologic Questionnaire to Assess Past Year Physical Activity in 
Adolescents. Am J Epidemiol 142:191-201, 1995 
2 Baker FC, Driver HS, Rogers GG, Paiker J, Mitchell D: High nocturnal body temperatures and 
disturbed sleep in women with primary dysmenorrhea. Am J Physiol 277:E1013-1021, 1999 
3 Bassett DR, Jr., Cureton AL, Ainsworth BE: Measurement of daily walking distance-
questionnaire versus pedometer. Med Sci Sports Exerc 32:1018-1023, 2000 
4 Berlin JE, Storti KL, Brach JS: Using Activity Monitors to Measure Physical Activity in Free-
Living Conditions. Phys Ther 86:1137-1145, 2006 
5 Bernstein M, Sloutskis D, Kumanyika S, Sparti A, Schutz Y, Morabia A: Data-based Approach 
for Developing a Physical Activity Frequency Questionnaire. Am J Epidemiol 147:147-154, 
1998 
6 Bruni O, Russo PM, Violani C, Guidetti V: Sleep and migraine: an actigraphy study. Cephalgia 
24:134-139, 2004 
7 Collins SL, Moore RA, McQuay HJ: The visual analogue pain intensity scale: what is moderate 
pain in millimetres? Pain 72:95-97, 1997 
 124 
8 Conway JM, Seale JL, Jacobs DR, Jr., Irwin ML, Ainsworth BE: Comparison of energy 
expenditure estimates from doubly labeled water, a physical activity questionnaire, and physical 
activity records. Am J Clin Nutr 75:519-525, 2002 
9 Dawood MY: Dysmenorrhea. J Reprod Med 30:154-167, 1985 
10 Dawood MY: Primary dysmenorrhea: advances in pathogenesis and management. Obstet 
Gynecol 108:428-441, 2006 
11 Esliger DW, Tremblay MS: Technical reliability assessment of three accelerometer models in 
a mechanical setup. Med Sci Sports Exerc 38:2173-2181, 2006 
12 Fordyce W, McMahon R, Rainwater G, Jackins S, Questad K, Murphy T, De Lateur B: Pain 
complaint-exercise performance relationship in chronic pain. Pain 10:311-321, 1981 
13 Freedson PS, Miller K: Objective monitoring of physical activity using motion sensors and 
heart rate. Res Q Exerc Sport 71:S21-29, 2000 
14 French L: Dysmenorrhea. Am Fam Physician 71:285-291, 2005 
15 Friedenreich CM, Courneya KS, Neilson HK, Matthews CE, Willis G, Irwin M, Troiano R, 
Ballard-Barbash R: Reliability and Validity of the Past Year Total Physical Activity 
Questionnaire. Am J Epidemiol 163:959-970, 2006 
16 Heil DP: Predicting activity energy expenditure using the Actical activity monitor. Res Q 
Exerc Sport 77:64-80, 2006 
 125 
17 Keen S, Dowell AC, Hurst K, Klaber Moffett JA, Tovey P, Williams R: Individuals with low 
back pain: how do they view physical activity? Fam Pract 16:39-45, 1999 
18 Kikuchi H, Yoshiuchi K, Ohashi K, Yamamoto Y, Akabayashi A: Tension-type headache and 
physical activity: an actigraphy study. Cephalgia 27:1236-1243, 2007   
19 Klesges RC, Eck LH, Mellon MW, Fulliton W, Somes GW, Hanson CL: The accuracy of self-
reports of physical activity. Med Sci Sports Exerc 22:690-697, 1990 
20 Kop WJ, Lyden A, Berlin AA, Ambrose K, Olsen C, Gracely RH, Williams DA, Clauw DJ: 
Ambulatory monitoring of physical activity and symptoms in fibromyalgia and chronic fatigue 
syndrome. Arthritis Rheum 52:296-303, 2005   
21 Korzun A, Young EA, Engelberg NC, Brucksch CB, Greden JF, Crofford LA: Use of 
actigraphy for monitoring sleep and activity levels in patients with fibromyalgia and depression. J 
Psychosom Res 52:439-443, 2002 
22 Krsnich-Shriwise S: Fibromyalgia syndrome: an overview. Phys Ther 77:68-75, 1997 
23 Landis CA, Frey CA, Lentz MJ, Rothermel J, Buchwald D, Shaver JLF: Self-reported sleep 
quality and fatigue correlates with actigraphy in midlife women with fibromyalgia. Nursing Res 
52:140-147, 2003 
24 Levine JA, Baukol PA, Westerterp KR: Validation of the Tracmor triaxial accelerometer 
system for walking. Med Sci Sports Exerc 33:1593-1597, 2001 
 126 
25 Long AC, Palermo TM, Manees AM: Brief report: using actigraphy to compare physical 
activity levels in adolescents with chronic pain and healthy adolescents. J Pediatr Psychol 
doi:10.1093, 2008   
26 Mahabir S, Baer DJ, Giffen C, Clevidence BA, Campbell WS, Taylor PR, Hartman TJ: 
Comparison of energy expenditure estimates from 4 physical activity questionnaires with doubly 
labeled water estimates in postmenopausal women. Am J Clin Nutr 84:230-236, 2006 
27 Mathie MJ, Coster AC, Lovell NH, Celler BG: Accelerometry: providing an integrated, 
practical method for long-term, ambulatory monitoring of human movement. Physiol Meas 
25:R1-20, 2004 
28 Meijer GA, Westerterp KR, Verhoeven FM, Koper HB, ten Hoor F: Methods to assess 
physical activity with special reference to motion sensors and accelerometers. IEEE Trans 
Biomed Eng 38:221-229, 1991 
29 Puyau MR, Adolph AL, Vohra FA, Zakeri I, Butte NF: Prediction of activity energy 
expenditure using accelerometers in children. Med Sci Sports Exerc 36:1625-1631, 2004 
30 Rashiq S, Koller M, Haykowsky M, Jamieson K: The effect of opioid analgesia on exercise 
test performance in chronic low back pain. Pain 106:119-125, 2003 
31 Shephard RJ, Vuillemin A: Limits to the measurement of habitual physical activity by 
questionnaires. Br J Sports Med 37:197-206, 2003 
 127 
32 Shih M, Hootman JM, Kruger J, Helmick CG: Physical activity in men and women with 
arthritis National Health Interview Survey, 2002. Am J Prev Med 30:385-393, 2006 
33 Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR: Patient non-compliance with 
paper diaries. BMJ 324:1193-1194, 2002 
34 Tanaka C, Tanaka S, Kawahara J, Midorikawa T: Triaxial accelerometry for assessment of 
physical activity in young children. Obesity 15:1233-1241, 2007 
35 Terrier P, Ladetto Q, Merminod B, Schutz Y: Measurement of the mechanical power of 
walking by satellite positioning system (GPS). Med Sci Sports Exerc 33:1912-1918, 2001 
36 Tudor-Locke CE, Myers AM: Methodological considerations for researchers and practitioners 
using pedometers to measure physical (ambulatory) activity. Res Q Exerc Sport 72:1-12, 2001 
37 Washburn RA, Jette AM, Janney CA: Using Age-Neutral Physical Activity Questionnaires in 
Research with the Elderly. J Aging Health 2:341-356, 1990 
38 Welk GJ, Schaben JA, Morrow JR, Jr.: Reliability of accelerometry-based activity monitors: a 
generalizability study. Med Sci Sports Exerc 36:1637-1645, 2004 
 39 Westerterp KR: Physical activity assessment with accelerometers. Int J Obes 23:S45-S49, 
1999 
40 Zhang WY, Li Wan Po A: Efficacy of minor analgesics in primary dysmenorrhea: a 
systematic review. Br J Obstet Gynaecol 105:780-789, 1998 
 128 
 
 
 
 
 
 
 
 
CHAPTER FIVE 
 
Conclusion 
 
 
 
 
 
 
 
 
 
 
 129 
Advances in the last three decades imply that prostaglandins are the primary agents in the 
pathogenesis of dysmenorrhoea (Dawood, 2006). Excessive production and release of 
endometrial prostaglandins (PG), especially PGF2 alpha, at menstruation, causes increased 
uterine contraction and uterine ischaemia (Dawood, 2006; Harel, 2006). Contraction of an 
ischaemic myometrium causes the pain (Dawood, 2006). Prostaglandin synthesis from 
arachidonic acid, and other precursors, is catalyzed by iso-enzymes of the cycloxygenase (COX) 
family; cycloxygenase-1 (COX-1) and cycloxygenase-2 (COX-2) (Funk, 2001). COX-1 is 
responsible for constitutive prostaglandin synthesis, which is involved in functions such as 
cytoprotection of the gastric mucosa and regulation of renal blood flow (Gabriel et al., 1991). In 
comparison, though it also has some adaptive functions (Hinz and Brune, 2001), COX-2 is up-
regulated during cellular trauma by pro-inflammatory agents (Frolich, 1997). It is likely that the 
formation of PGF2 alpha, in dysmenorrhoea, is COX-2 dependent, since in vitro studies have 
shown that inhibitors of the COX-2 iso-enzyme have significant relaxant effects on myometrial 
contractility (Slattery et al., 2001). In addition, the COX-2 isoform has been localised in the 
glandular epithelium of the human endometrium throughout the menstrual cycle with a 
significant increase in COX-2 immunostaining intensity observed premenstrually (Jones et al., 
1997).  
 
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the COX enzyme, leading to a reduction 
in prostaglandin production (Funk, 2001). NSAIDs are the best-established initial therapy for 
primary dysmenorrhoea; they decrease prostaglandins, especially PGF2 alpha, cause less vigorous 
contraction of the uterus, less ischaemia, and therefore less pain (Dawood, 2006; Harel, 2006). 
Historically, before the development of the selective and specific COX-2 inhibitors, conventional 
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NSAIDs, which were selective COX-1 inhibitors, or non-selective COX inhibitors, were 
prescribed to treat dysmenorrhoea, with varying degrees of success, but with a risk of causing 
gastrointestinal side-effects (Majoribanks et al., 2003). The selective and specific COX-2 
inhibitors, which spare COX-1, have been marketed as anti-inflammatory and analgesic agents, 
without the gastric side-effects associated with suppression of COX- 1 activity (Warner et al., 
1999; Hinz and Brune, 2001), though, as has recently come to widespread attention, the chronic 
inhibition of COX-2, especially in elderly patients, can result in potentially lethal renal and 
cardiovascular side effects (FitzGerald, 2004). However, in young and healthy women with 
dysmenorrhoea, inhibition of COX-2, via the specific COX-2 inhibitors, has not been associated 
with harmful side-effects (Daniels et al., 2002; Malmestrom et al., 2003; Edwards et al., 2004; 
Bitner et al., 2004). The main determinant when selecting a COX inhibitor for dysmenorrhoea is 
likely to be its potential to safely alleviate menstrual pain. If the iso-enzyme involved in 
generating dysmenorrhoea is COX-2, then, theoretically, specific COX-2 inhibitors might offer 
superior efficacy to selective COX-1 and non-selective COX inhibitors. The efficacy of specific 
COX-2 inhibitors, versus placebo, in relieving dysmenorrhoea has been shown, but has not been 
proven to exceed that of the selective COX-1 inhibitor, naproxen (Morrison et al., 1999; Sahin et 
al., 2003;  Harel, 2004). Before my research, no studies had investigated the analgesic efficacy of 
three COX-inhibitors, covering a spectrum of COX-2 selectivity, in attenuating dysmenorrhoea 
in the same women. 
 
In Chapter 2, I therefore investigated the antinociceptive efficacy of a specific COX-2 inhibitor 
promoted for treatment of dysmenorrhoea (rofecoxib), a selective COX-2 inhibitor (meloxicam), 
and a non-selective COX inhibitor (diclofenac potassium, an agent which appears not to have 
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been investigated previously), in otherwise-healthy young women with primary dysmenorrhoea. 
The primary outcome of my study was that two of the agents tested, namely diclofenac potassium 
(a non-selective COX inhibitor) and rofecoxib (a specific COX-2 inhibitor), provided excellent 
pain relief for the women, in spite of the subjects recording their menstrual pain on the 100mm 
VAS as 70/100, which is severe pain, and in spite of them reporting their previous management 
routines for dysmenorrhoea as being unsuccessful. For half of the women, their unsuccessful 
previous management of the pain included self-medication with agents containing COX 
inhibitors. Irrespective of whether the VAS or MPQ (PRI and PPI) was used to measure the pain 
intensity, the pain relief provided by both diclofenac potassium and by rofecoxib exceeded 50% 
for more than half of the cohort each time a capsule was taken. Pain researchers consider 50% 
relief as successful clinical pain management (Moore et al., 1996). Diclofenac potassium 
provided complete pain relief (that is pain relief statistically not different to 100% for the cohort), 
as measured by at least some indices, after three of the capsules, whereas rofecoxib provided 
complete pain relief after the fourth capsule only. When the women were treating themselves 
with placebo, they continued treatment for 63 hours, on average, but stopped more than half a day 
earlier when they had used either diclofenac potassium or rofecoxib. Stopping the placebo 
medication at 63 hours probably signals the end of the dysmenorrhoea, and stopping earlier, as 
occurred with administration of diclofenac and rofecoxib, implies early termination of the pain. 
The doses of rofecoxib and diclofenac potassium self-selected by the women to not only 
successfully decrease their menstrual pain, but also decrease the duration of the dysmenorrhoea,   
were somewhat less than the dose recommended by the manufactures and approved by regulatory 
authorities.   
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Although diclofenac potassium does not appear to have been investigated previously, my results 
are in accordance with studies that found that recommended doses of diclofenac sodium, the 
sodium salt equivalent of diclofenac potassium, alleviated dysmenorrhoea (Riihiluoma et al., 
1981; Majoribanks et al., 2003), and were as effective as the selective COX-1 inhibitors naproxen 
and ibuprofen, in relieving dysmenorrhoea (Majoribanks et al., 2003). In my study, 
recommended daily doses of the specific COX-2 inhibitor rofecoxib, and non-selective COX 
inhibitor diclofenac potassium, were both extremely effective in relieving dysmenorrhoea, with 
diclofenac potassium showing some superiority in some secondary outcomes. My findings on the 
efficacy of rofecoxib in relieving dysmenorrhoea are consistent with those of other investigators 
who reported that a recommended dose of rofecoxib provided relief similar to that provided by 
naproxen sodium, a selective COX-1 inhibitor (Morrison et al., 1999; Sahin et al., 2003; Bitner et 
al., 2004; Edwards et al., 2004). Though the efficacy of rofecoxib in the treatment of 
dysmenorrhoea has been demonstrated previously, it has primarily been in straightforward 
clinical trials, without the detailed measurement of pain intensity which I undertook. Also, none 
of the previous investigations has compared rofecoxib directly with the selective COX-2 inhibitor 
meloxicam. In my study, meloxicam was more effective than placebo, but less effective than 
rofecoxib and diclofenac potassium in relieving dysmenorrhoea. When the women were taking 
meloxicam, they stopped treatment only 8 hours sooner than they stopped placebo. Meloxicam 
has been found to be as effective as mefenamic acid, a non-selective COX inhibitor, in relieving 
dysmenorrhoea (De Mello et al., 2004), but less than half of the women rated the pain relief of 
the two drugs as good. The recommended daily dose for meloxicam is 7.5 to 15mg per day. In 
my study the women self-medicated with 15 mg per day, and it may well be that the 
recommended daily dose is inadequate to attenuate dysmenorrhoea. That meloxicam provided 
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efficacy less than diclofenac potassium and rofecoxib, and that rofecoxib was as effective as 
naproxen in alleviating pain, illustrates that, though it is the COX-2 iso-enzyme that is likely to 
be involved in dysmenorrhoea, relative selectivity for that iso-enzyme does not necessarily 
compensate for lack of potency in COX inhibition. Therefore, as shown in my study, the non-
selective COX inhibitor diclofenac potassium, which has equal selectivity for both COX-1 and 
COX-2, is more effective in relieving menstrual pain than rofecoxib, a specific COX-2 inhibitor 
that inhibits COX-2 strongly with only weak activity against COX-1 (Figure 4, pg. 30). 
Similarly, as shown in other studies, naproxen sodium, which inhibits COX-1 and COX-2 with 
preference towards COX-1, is as effective in alleviating dysmenorrhoea as rofecoxib, a specific 
COX-2 inhibitor, which inhibits COX-2 strongly with only weak activity against COX-1 
(Morrison et al., 1999; Sahin et al., 2003). Furthermore, the efficacy of other specific COX-2 
inhibitors such as valdecoxib, etoricoxib and lumiracoxib, which have greater specificity for 
COX-2 than does rofecoxib (Figure 4. pg. 30), have been shown to be as effective as the 
selective COX-1 inhibitor naproxen, in alleviating dysmenorrhoea (Daniels et al., 2002; 
Malmstrom et al., 2003; Bitner et al., 2004). Therefore, relative selectivity for COX-2 does not 
necessarily imply potency in COX-2 inhibition. 
 
I suggest that women with primary dysmenorrhoea medicate with a NSAID that has the least 
potential to cause side-effects. Unfortunately, administration of naproxen in women with 
dysmenorrhoea has been associated with a greater risk of gastric ulceration (Marjoribanks et al., 
2003). In my study, the women who received diclofenac potassium for their menstrual pain did 
not report any side-effects and, in another study, acute administration of diclofenac sodium for 
menstrual pain was not associated with side-effects (Riihiluoma et al., 1981). In comparison, 
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chronic oral administration of diclofenac sodium, compared to placebo and valdecoxib, in 
patients with rheumatoid arthritis, was associated with increased gastric side-effects (Pavelka et 
al., 2003). However, acute administration of diclofenac sodium, in patients after laparoscopy, did 
not cause increased side-effects (Gillberg et al., 1993). Therefore, acute administration of 
diclofenac potassium, as would occur in women with dysmenorrhoea, seems to be a safe and 
effective means of relieving menstrual pain. Although there was great concern over the potential 
of chronic administration of specific COX-2 inhibitors to cause fatal cardiovascular side-effects 
in elderly patients (FitzGerald, 2004), these side-effects are unlikely to occur in young, healthy 
women who are taking the specific COX-2 inhibitors for two to four days every month. 
Certainly, in the studies that have investigated the analgesic efficacy of the specific COX-2 
inhibitors rofecoxib, etoricoxib, lumiracoxib and valdecoxib in dysmenorrhoea, the specific 
COX-2 inhibitors had an adverse-effects profile similar to placebo (Daniels et al., 2002; 
Malmestrom et al., 2003; Edwards et al., 2004; Bitner et al., 2004). In my study, rofecoxib 
administration did not result in any side-effects in the women. Therefore, for an acute but 
recurrent painful condition such as primary dysmenorrhoea, the non-selective COX inhibitor 
diclofenac potassium and the specific COX-2 inhibitors rofecoxib, etoricoxib, lumiracoxib and 
valdecoxib are effective, and safe, in alleviating dysmenorrhoea. However, studies would need to 
determine the safety of diclofenac potassium and the specific COX-2 inhibitors when the drugs 
are used for two-to-three days of each month on a long-term basis.   
 
I did not impose a regimen of administration on the women in the study, but allowed them to 
self-administer the assigned medication at whatever interval and for whatever duration they felt 
necessary, subject to not exceeding maximum doses approved by regulatory authorities. I believe 
 135 
that my self-administration regimen mimics better what women faced with managing their 
dysmenorrhoea will do, than does a fixed-schedule regimen. Other studies, investigating the 
antinociceptive efficacy of NSAIDs in alleviating dysmenorrhoea, have not used this approach. 
The women have been required to medicate at pre-determined times during the day, and for one 
or two days only. Such a regimen is useful in studies or clinical trials where the efficacy of a 
drug, or more than one drug, is being investigated in a large cohort of women, and analysis and 
interpretation of the data is not complicated by infrequent or over-frequent drug administration. 
However, such a regimen does not allow investigators to assess the time-course of the menstrual 
pain, and to determine whether the administered drug is able to decrease the duration of 
dysmenorrhoea. A self-administration regimen, as used in my study, provides valuable insights 
into the attitudes of the women towards dysmenorrhoea, and its management. Even when their 
treatment was completely unsuccessful (the case with placebo) or only partially successful 
(meloxicam), the women in my study chose not to take rescue medication. They took no more 
than four capsules of any medication, and adhered to what looked like a twice-daily regimen even 
though, at least in the case of placebo, their pain intensity had attenuated hardly at all by the time 
they took their last capsule. Their behavior is a possible reflection that dysmenorrhoea is a burden 
which women have to bear, and that the treatment will not be successful.  
 
Certainly, the view held by the women in my study is not unique to women in South Africa. 
Despite progress in understanding the pathophysiology of dysmenorrhoea and the availability of 
effective treatments, many women with dysmenorrhoea in other countries such as the United 
States, Australia and Thailand, do not seek medical advice, are under-treated (Harel, 2002) and 
are ignorant about the pharmacological treatment of dysmenorrhoea (Johnson, 1988; Tangchai et 
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al., 2004; Chen et al., 2006). In addition, recent studies have shown that many girls are unaware 
of the causes of dysmenorrhoea (Sharma and Gupta, 2003; Houston et al., 2006), and therefore do 
not seek medical advice for their dysmenorrhoea (Andersch and Milsom, 1982; Wilson and Keye, 
1989; Hillen et al., 1999; Banikarim et al., 2000). Often adolescent girls and young women fear 
that a medical consultation by a general practitioner or gynaecologist may reveal them to be 
different or abnormal from their peers (Malonne and van Hoek, 2003). In these women, 
dysmenorrhoea is unfortunately viewed as burden which women have to bear (Johnson, 1988; 
Wilson and Keye, 1989).  
 
The women in my study were not unique in the way they attempted to manage their 
dysmenorrhoea; as did the subjects of other studies (Johnson, 1988), the women in my study had 
used mild analgesics and non-pharmaceutical measures to try to alleviate their pain. The women 
in my study seemed to not expect effective treatment for dysmenorrhoea, which might explain 
why none of them sought rescue medication. The lack of efficacy of their pre-study medication 
may also explain why there was no placebo response, since the women instinctively believed the 
medication would not attenuate their menstrual pain and therefore, they were not anticipating 
effective pain relief. The lack of a placebo response was a major surprise to me. In studies of 
antinociception in which subjects have an expectation of pain relief, placebos invariably are 
effective at least in some patients, irrespective of the aetiology of the pain; placebo analgesia is 
mediated by endogenous opioids (Benedetti et al., 2003).  Indeed previous investigations of 
efficacy of pharmaceutical management of dysmenorrhoea have reported that 15-33% of patients 
with primary dysmenorrhoea responded favorably to placebo administration (Fedele et al., 1989). 
It may be that the subjects of the previous investigations had had better previous experience with 
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management of their pain. I suspect, though, that the main difference between my investigation 
and the previous ones is that the women in my study never were asked to give an opinion about 
the outcome of the interventions; they had to apply themselves to considering and rating their 
pain repetitively, using authenticated pain indices. 
  
In my study, I assessed menstrual pain using two well-authenticated scales; a 100mm visual 
analogue scale (VAS), and the McGill Pain Questionnaire (MPQ). The VAS allows only for 
assessment of pain intensity. The MPQ allows for assessment of pain intensity, via the pain 
response index (PRI) and present pain intensity (PPI) index, and assessment of the quality of 
pain, via the words chosen. In the major studies investigating the antinociceptive efficacy of 
NSAIDs in alleviating dysmenorrhoea (Tables 1, 2, 3, and 4; Chapter 1) the MPQ has not been 
used as a method of measuring the intensity of pain, and the VAS has been used as a measure of 
intensity of pain by only very few of the investigators. In the studies described in Tables 1-4 
(Chapter 1), the investigators have measured pain relief by asking the women to rate their 
intensity of pain using verbal rating and numerical rating scales and then these values have been 
used to calculate the pain-relieving efficacy of the medication. In other studies, the analgesic 
efficacy of the medication was determined using verbal and numerical scales, and then expressed 
as the number of women reporting moderate-to-excellent pain relief, or as the number of 
menstrual cycles where the treatment gave moderate-to-good pain relief. Verbal rating scales 
consist of a series of verbal pain descriptors listed from least to most intense (e.g., no pain, mild, 
moderate and severe), whereas numerical rating scales require the patient to choose a numerical 
value which corresponds to their intensity of pain (e.g., 0=no pain, 1=mild pain, 2=moderate pain 
and 3 =severe pain).  Although research has shown that the verbal rating scale, numerical rating 
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scale and the VAS correlate highly with each other (Ekblom and Hansson, 1988; Bijur et al., 
2003), the VAS has emerged as a superior scale to measure intensity of pain because of its ratio 
scale properties (Price and Harken, 1987; Price et al., 1983). Therefore, VAS measurements 
obtained at multiple points in time, or from different patients, can be used to calculate percentage 
differences in pain intensity (Bijur et al., 2001). However, because the VAS requires the ability to 
represent a sensory phenomenon geometrically, a competency which requires reasonable 
education, and which may not be interpreted identically in different cultures, the VAS is not 
routinely used in dysmenorrhoea studies.  
 
The reason for the lack of use of the MPQ in dysmenorrhoeic studies is because the MPQ is time-
consuming and difficult to administer; it is therefore not suitable for studies were large cohorts of 
women are required to rate their pain many times per day.  Therefore, in an attempt to try and 
simplify the assessment of dysmenorrhoea for future studies, I determined if there was a 
correlation between the pain intensity, as assessed by the MPQ (the PRI and PPI), and the pain 
intensity as measured by the VAS, in the women with dysmenorrhoea. An important outcome of 
my study was that the intensity of dysmenorrhoea can be assessed well using any of the PRI, PPI, 
or VAS. However, the PRI, which requires implementation of the full MPQ, and requires 
proficiency in the language of the MPQ, was the most difficult to apply and most time-
consuming. I propose that if the objective is to assess only the intensity of dysmenorrhoea, it is 
not necessary to use the PRI, and the VAS, a more sensitive index than the PPI, is most suitable. 
However, as mentioned in the above paragraph, the VAS requires reasonable education, and may 
not be interpreted identically in different cultures. So, depending on the patient population, it may 
not be possible to use the VAS to assess pain intensity. In my study, the VAS proved to be an 
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accurate and simple index to assess the intensity of dysmenorrhoea in the university students. 
Although the MPQ is time-consuming to administer, the words chosen in the questionnaire, such 
as “cramping”, “annoying” or “fearful” are useful in describing the quality of the pain. Certainly, 
if the aim of a future research study or clinical trial is to describe the quality of pain, and the 
patient population is proficient in the language of the MPQ, the MPQ is an essential assessment 
tool to include in the investigation. However, subject compliance may be poor in studies with 
large cohorts of women, which require the women to complete many MPQs over the day, or over 
many days. In these studies, the VAS is a reliable and valid measure of intensity of pain, but does 
not elicit information about the quality of pain.      
 
When their menstrual pain was not treated, the intensity of pain experienced by the women in my 
study ranged from 55mm to 70mm on a 100mm VAS, which was similar to that reported by the 
subjects of other dysmenorrhoea studies (Johnson, 1988; Majoribanks et al., 2003), and was 
similar in intensity to the pain reported by other patients with arthritis and dental pain.  It is 
therefore not surprising that dysmenorrhoea, if untreated, can be debilitating. Like patients who 
have painful conditions such as fibromyalgia, lower back pain and osteo-arthritis, women with 
dysmenorrhoea report decreased physical and functional activity (Krsnich-Schriwise, 1997; 
Rashiq et al., 2003; French, 2005; Shih et al., 2006). Women experiencing moderate-to-severe 
dysmenorrhea subjectively report decreased physical activity levels and decreased participation 
in sporting events (Andersch and Milsom, 1982; Sundell et al., 1990; Banikarim et al., 2000; 
Tangchai et al., 2004). In questionnaire and retrospective surveys, women listed menstrual 
symptoms such as dysmenorrhea, fatigue, fluid retention and weight gain as limiting factors on 
sports activity and performance (Bale and Davis, 1983; Bale and Nelson, 1985; Lebrun, 1993).   
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Subjective and retrospective reports of the effect of pain on exercise performance and functional 
status are often inaccurate (Conway et al., 2002). Therefore, a controlled and standardized 
laboratory protocol is useful to assess whether moderate-to-severe dysmenorrhoea does decrease 
performance and, if so, quantify the decrease in exercise and functional performance. In Chapter 
3, I described the design of a specific exercise testing protocol to assess the impact of 
dysmenorrhoea on leg strength as well as the impact of dysmenorrhoea on functional activities 
such as walking uphill and on a task-specific test involving lumbar flexion and extension. As 
shown in my study in Chapter 2, diclofenac potassium was far superior to placebo in attenuating 
menstrual pain.  I predicted that pain in the pelvic region would impair movement around the 
pelvis, but was unaware of any standard test that targets this region of the body. Therefore, I 
designed a task-specific test that would assess the functional ability of the women to repeatedly 
bend down, pick up a light weight, carry the weight over a short distance, and then reach up to 
place the weight on a ledge above their head (Figure 1, Chapter 3). The women completed the 
task as quickly as possible and their time to complete the task was used as a measure of their 
functional performance. The women’s decreased performance in the functional test, when given 
placebo for their menstrual pain, highlights the detrimental impact that dysmenorrhoea can have 
on a functional activity such as flexing at the waist and reaching upwards. A recommended dose 
of diclofenac potassium not only attenuated the menstrual pain, but restored the women’s 
performance in the functional test to that measured when they were in a pain-free phase of the 
menstrual cycle. The task-specific test is a novel tool that can be used, in future studies, to 
measure the effectiveness of pharmacological interventions, or other types of treatment, in 
restoring functional activity in women with moderate-to-severe dysmenorrhoea. Furthermore, I 
also assessed the ability of the women to walk uphill on a motorised treadmill, and used a 
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standardised leg-press machine to measure their lower limb leg strength. When given placebo for 
their menstrual pain, the women chose to walk for 25% less time on the treadmill and stopped 
walking at a lower heart rate and rating of perceived exertion, compared to when they were in a 
pain-free phase of the menstrual cycle, implying that it was the pain, and not cardiovascular 
fatigue, that limited their exercise performance. When the women were receiving placebo for 
their menstrual pain, their leg strength decreased by 20% compared to when they were in a pain-
free phase of the menstrual cycle. A recommended dose of diclofenac potassium, an unbanned 
substance, not only attenuated the menstrual pain, but restored the women’s exercise time on the 
treadmill, and leg strength, to levels measured when they were in the late-follicular pain-free 
phase of the menstrual cycle. I have shown, therefore, that it was menstrual pain, and not other 
consequences of menstruation, that was associated with decreased exercise performance. 
Although I did not assess performance in a sporting event, or in an occupational setting, where 
motivation may enable an individual to exercise or work through the pain, I have shown that 
women need not endure menstrual pain. My study is the first to quantify the decrease in 
dysmenorrhoea-related exercise performance, and to show the efficacy of a recommended daily 
dose of diclofenac potassium in restoring exercise performance and functional ability. 
 
Although I was successful in quantifying the decrease in structured physical activity in the 
women with dysmenorrhoea, I still wished to investigate if there were other ways of objectively 
assessing, and quantifying, the detrimental impact that dysmenorrhoea may have on the activity 
of daily life. Conventional assessment of daily activity using questionnaires or diaries requires 
rigorous patient compliance, and can be inaccurate (Conway et al., 2002; Stone et al., 2002). 
Activity data loggers (actigraphy) allow for an objective assessment of physical activity, and are 
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particularly useful outside the laboratory setting, in free-living people (Westerterp, 1999). 
Typically, activity data loggers are small, unobtrusive devices, worn on the hip, wrist or ankle, 
which can measure activity minute-by-minute, with little intervention by the observer, over days, 
weeks or months (Westerterp, 1999; Mathie et al., 2004; Welk et al., 2004). Furthermore, activity 
data loggers are a valid and reliable tool for the measurement of dynamic physical activities, such 
as walking and running (Esliger and Tremblay, 2006). In patients experiencing pain, actigraphy 
has emerged as a useful tool to measure the debilitating effects of the pain, or to detect the effects 
of physical, surgical or pharmacological interventions. Actigraphy has been used to show a 
decrease in physical activity in patients with tension-type headache (Kikuchi et al., 2007), women 
with fibromyalgia (Korzun et al., 2002; Kop et al., 2005), and in adolescents with chronic pain 
(Long et al., 2008). In Chapter 4, I assessed whether a hip-mounted miniature activity data logger 
was able to measure quantitatively the reduced physical activity reported by women with primary 
dysmenorrhoea. I included women without a history of dysmenorrhoea in the study to investigate 
whether menstrual pain, or menstruation itself, was responsible for the any decrease in physical 
activity.    
 
In the women with a history of dysmenorrhoea, physical activity, recorded every hour by an 
activity data logger, over three days of menstruation, was lower than that recorded when the 
women were in a pain-free phase of their menstrual cycles, on days of the week matched to those 
of the three days of menstrual pain. Although the intensity of pain varied over the three days of 
menstruation, the 24 hour physical activity of the group of women was similar on these three 
days, and depressed to about two-thirds of the 24 hour activity measured when they were in a 
pain-free phase of the menstrual cycle. Both pain intensity and depression of physical activity 
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varied between the women in my cohort, and, on the day of the worst menstrual pain, the awake 
physical activity actually was correlated inversely and linearly with the pain intensity 
experienced by that woman. However, according to the regression co-efficient, pain intensity 
accounted for less than half of the variability in physical activity between the women. The 
practical implication of my results is that one should expect any women with a history of 
moderate-to-severe menstrual pain to have similarly reduced voluntary physical activity over 
three days of menstruation. 
 
The depression in physical activity did not occur in the women without a history of 
dysmenorrhoea. Even though they too experienced some mild pain during menstruation, the pain 
they experienced did not decrease their physical activity. I have shown, therefore, that it was 
menstrual pain, and not other consequences of menstruation, that was associated with decreased 
physical activity. However, in hindsight, I did not ask the women to record the heaviness of their 
menstrual flow or ask them to record the number of feminine hygiene products used during 
menstruation. Heavy menstrual flow has been identified as a risk factor for dysmenorrhoea (Klein 
and Litt, 1981; Andersch and Misom, 1982; Teperi and Rimpela, 1989), and some investigators 
have reported heavier and longer menstrual periods in women with dysmenorrhoea (Riihiluoma 
et al., 1981). Therefore, I cannot exclude the possibility that heavy menstrual flow in the women 
with dysmenorrhoea, and not only pain, may have decreased their physical activity. In future 
studies, questionnaires should include questions about the heaviness of the menstrual flow, and 
increased use of feminine hygiene products.        
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My data showed, however, that there was no change in nocturnal activity between the follicular 
(no pain) and menstrual phases, in the women with dysmenorrhoea, and nor was there any 
difference in nocturnal physical activity during menstruation between the women with and 
without a history of dysmenorrhoea. As shown by other researchers, dysmenorrhoea does alter 
sleep architecture (Baker et al., 1999), including increasing awakenings during sleep, but, in the 
women in my study, did not result in nocturnal activity, such as increased in-bed movement or 
walking around, which would have been detected by the data loggers. Other researchers have 
used actigraphy to show disturbed sleep in other painful conditions such as fibromyalgia (Korzun 
et al., 2002, Landis et al., 2003) and migraine (Bruni et al., 2004). More-sensitive triaxial 
accelerometers, attached to the wrist, might detect increased restlessness in bed, associated with 
dysmenorrhoea, in which case I would have underestimated the depression in physical activity 
over the full 24 hours. Triaxial accelerometers also might detect more-subtle changes in diurnal 
physical activity in women with dysmenorrhoea. In my study, an omni-directional activity data 
logger was attached at each woman’s waist and was positioned to be most sensitive to movement 
in the vertical plane, such as that generated by walking. So the physical activity that I have shown 
to be so markedly depressed was the activity of walking, or other gross body movement. Future 
studies should use triaxial accelerometers as a more sensitive, yet objective, measure of diurnal 
and nocturnal physical activity.  
 
My measurements of the voluntary physical activity of women with a history of dysmenorrhoea 
differ from all previous measurements in that they were objective measurements, recorded by 
actigraphy, via activity data loggers, and required no compliance from the women other than 
removing the logger for bathing or showering. I believe that measurements of voluntary physical 
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activity may be used as indices of quality of life.  Since, in the women with a history of 
dysmenorrhoea, activity was suppressed even when pain was mild, the success of treatment for 
dysmenorrhoea, arguably, would be judged better on the degree to which it restores voluntary 
activity than to which it relieves pain. Activity data loggers allow for an objective assessment of 
physical activity, and are particularly useful outside the laboratory or hospital setting, in free-
living people. They are unobtrusive, do not impede movement, and are compatible with most 
daily activities. I have shown that activity data loggers are able to quantify the reduced physical 
activity reported by women with primary dysmenorrhoea. Though the inexpensive loggers I used 
served my purpose adequately, more-sensitive loggers based on triaxial accelerometers are 
available commercially. However, before actigraphy can become a standard tool to objectively 
measure the extent to which pain interferes with normal daily life, researchers need to show an 
agreement in the results obtained from comprehensive and validated physical activity 
questionnaires, the data obtained from activity data loggers, and the data obtained from direct or 
indirect calorimetry, or analysis of doubly-labelled body water.  
 
Primary dysmenorrhoea occurs commonly in women of child-bearing age, and, if poorly 
managed, as it often is, can result in a high degree of school and work absenteeism, and 
decreased physical well-being (Klein and Litt, 1981; Sundell et al., 1990; Banikarim et al., 2000; 
Burnett et al., 2005). I have shown that moderate-to-severe dysmenorrhoea impacts negatively on 
a woman’s ability to perform a functional task involving lumbar flexion and extension and 
decreases her ability to perform exercise using her lower limbs. Furthermore, the women’s 
physical activity, as measured objectively by data loggers, was significantly decreased, by 
approximately 35%, compared to when they were not menstruating. Certainly, such a decrease in 
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voluntary physical activity could decrease productivity and decrease quality of life. However, 
women need not endure dysmenorrhoea. I have shown that recommended doses of rofecoxib, or 
diclofenac potassium, are excellent, and safe, agents that not only decrease the duration of 
dysmenorrhoea, but significantly attenuate dysmenorrhoea. However, the long-term safety of 
diclofenac potassium and rofecoxib has still to be ascertained. The ability of diclofenac 
potassium to significantly reduce menstrual pain and reverse the negative impact of 
dysmenorrhoea on exercise performance, and functional activities that require lumbar flexion and 
extension, offers a major advance in improving the quality of life of women with primary 
dysmenorrhoea.   
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